BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ginès A, Escorsell A, Ginès P, Saló J, Jiménez W, Inglada L, Navasa M, Clària J, Rimola A, Arroyo V. Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology 1993;105:229-36. [PMID: 8514039 DOI: 10.1016/0016-5085(93)90031-7] [Cited by in Crossref: 609] [Cited by in F6Publishing: 603] [Article Influence: 20.3] [Reference Citation Analysis]
Number Citing Articles
1 Matchett CL, Simonetto DA, Kamath PS. Renal Insufficiency in Patients with Cirrhosis. Clin Liver Dis 2023;27:57-70. [PMID: 36400467 DOI: 10.1016/j.cld.2022.08.010] [Reference Citation Analysis]
2 Wong F. Hepatorenal syndrome and acute kidney injury in cirrhosis. Cardio-Hepatology 2023. [DOI: 10.1016/b978-0-12-817394-7.00003-6] [Reference Citation Analysis]
3 Li X, Yuan F, Zhou L. Organ Crosstalk in Acute Kidney Injury: Evidence and Mechanisms. J Clin Med 2022;11. [PMID: 36431113 DOI: 10.3390/jcm11226637] [Reference Citation Analysis]
4 Singal AK, Kuo YF, Reddy KR, Bataller R, Kwo P. Healthcare burden and outcomes of hepatorenal syndrome among cirrhosis-related hospitalisations in the US. Aliment Pharmacol Ther 2022;56:1486-96. [PMID: 36196562 DOI: 10.1111/apt.17232] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Bai Z, Wang L, Lin H, Tacke F, Cheng G, Qi X. Use of Human Albumin Administration for the Prevention and Treatment of Hyponatremia in Patients with Liver Cirrhosis: A Systematic Review and Meta-Analysis. JCM 2022;11:5928. [DOI: 10.3390/jcm11195928] [Reference Citation Analysis]
6 Wakil A, Mohamed M, Tafesh Z, Niazi M, Olivo R, Xia W, Greenberg P, Pyrsopoulos N. Trends in hospitalization for alcoholic hepatitis from 2011 to 2017: A USA nationwide study. World J Gastroenterol 2022; 28(34): 5036-5046 [DOI: 10.3748/wjg.v28.i34.5036] [Reference Citation Analysis]
7 Yang C, Xiong B. A comprehensive review of prognostic scoring systems to predict survival after transjugular intrahepatic portosystemic shunt placement. Portal Hypertension & Cirrhosis 2022;1:133-144. [DOI: 10.1002/poh2.28] [Reference Citation Analysis]
8 Zheng F, Ye X, Chen Y, Wang H, Fang S, Shi X, Lin Z, Lin Z. Treatment of hyponatremia in children with acute bacterial meningitis. Front Neurol 2022;13:911784. [DOI: 10.3389/fneur.2022.911784] [Reference Citation Analysis]
9 Ponzo P, Campion D, Rizzo M, Roma M, Caviglia GP, Giovo I, Rizzi F, Bonetto S, Saracco GM, Alessandria C. Transjugular intrahepatic porto-systemic shunt in cirrhotic patients with hepatorenal syndrome - chronic kidney disease: Impact on renal function. Dig Liver Dis 2022;54:1101-8. [PMID: 34625366 DOI: 10.1016/j.dld.2021.09.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
10 Habas E, Ibrahim AR, Moursi MO, Shraim BA, Elgamal ME, Elzouki AN. Update on hepatorenal Syndrome: Definition, Pathogenesis, and management. Arab J Gastroenterol 2022:S1687-1979(22)00005-3. [PMID: 35473682 DOI: 10.1016/j.ajg.2022.01.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Shweta K, Neelima C, Madhuri K. Study of Clinical Profile and Outcome in Patients of Alcohol Induced Chronic Liver Disease with Hepato Renal Syndrome. MVP J M S 2022. [DOI: 10.18311/mvpjms/2021/v8i2/307] [Reference Citation Analysis]
12 Wang X, Jamil K. Pharmacokinetic and pharmacodynamic analyses of terlipressin in patients with hepatorenal syndrome. AAPS Open 2022;8. [DOI: 10.1186/s41120-022-00052-7] [Reference Citation Analysis]
13 Ubrangala RK, Ravishankar A. STUDY OF RENAL RESISTIVITY INDEX IN LIVER CIRRHOSIS IN PREDICTING THE INCIDENCE OF HEPATORENAL SYNDROME. PIJR 2022. [DOI: 10.36106/paripex/7907344] [Reference Citation Analysis]
14 Praharaj DL, Anand AC. Clinical Implications, Evaluation, and Management of Hyponatremia in Cirrhosis. J Clin Exp Hepatol 2022;12:575-94. [PMID: 35535075 DOI: 10.1016/j.jceh.2021.09.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
15 Terres AZ, Balbinot RS, Muscope ALF, Longen ML, Schena B, Cini BT, Luis Rost G, Balensiefer JIL, Eberhardt LZ, Balbinot RA, Balbinot SS, Soldera J. Evidence-based protocol for diagnosis and treatment of hepatorenal syndrome is independently associated with lower mortality. Gastroenterología y Hepatología (English Edition) 2022;45:25-39. [DOI: 10.1016/j.gastre.2021.02.009] [Reference Citation Analysis]
16 O’riordan A, Ware T. Hepatology and the Kidney. Primer on Nephrology 2022. [DOI: 10.1007/978-3-030-76419-7_36] [Reference Citation Analysis]
17 Zgheib NK, Lertora JJ, Branch RA. Effect of liver disease on pharmacokinetics. Atkinson's Principles of Clinical Pharmacology 2022. [DOI: 10.1016/b978-0-12-819869-8.00005-7] [Reference Citation Analysis]
18 Al-jedai A, Alabdulkarim Z, Alkortas D, Alsebayel M, Alkhail F, Elsiesy H. Efficacy and predictors to response of octreotide and midodrine combination in patients with hepatorenal syndrome. Saudi J Clin Pharm 2022;1:69. [DOI: 10.4103/sjcp.sjcp_4_22] [Reference Citation Analysis]
19 Kozich EA, Krasavtsev EL. Predictors of the development of hepatorenal syndrome. jour 2021;18:69-73. [DOI: 10.51523/2708-6011.2021-18-4-9] [Reference Citation Analysis]
20 Liu S, Meng Q, Xu Y, Zhou J. Hepatorenal syndrome in acute-on-chronic liver failure with acute kidney injury: more questions requiring discussion. Gastroenterol Rep (Oxf) 2021;9:505-20. [PMID: 34925848 DOI: 10.1093/gastro/goab040] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
21 Sasso R, Abou Yassine A, Deeb L. Predictors of Development of Hepatorenal Syndrome in Hospitalized Cirrhotic Patients with Acute Kidney Injury. J Clin Med 2021;10:5621. [PMID: 34884323 DOI: 10.3390/jcm10235621] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
22 Hieu TH, Hashan MR, Morsy S, Tawfik GM, Cucè F, Sharma A, Quynh TTH, Faraj HA, Qarawi ATA, Huy NT. Hyponatremia in tuberculous meningitis: A systematic review and meta-analysis. Indian J Tuberc 2021;68:516-26. [PMID: 34752323 DOI: 10.1016/j.ijtb.2021.06.004] [Reference Citation Analysis]
23 Chaney A. A Review for the Practicing Clinician: Hepatorenal Syndrome, a Form of Acute Kidney Injury, in Patients with Cirrhosis. Clin Exp Gastroenterol 2021;14:385-96. [PMID: 34675586 DOI: 10.2147/CEG.S323778] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
24 Sheng X, Chen W, Xu Y, Lin F, Cao H. Higher Mean Corpuscular Hemoglobin Concentration is Associated with Worse Prognosis of Hepatorenal Syndrome: A Multicenter Retrospective Study. Am J Med Sci 2021:S0002-9629(21)00356-6. [PMID: 34624233 DOI: 10.1016/j.amjms.2021.06.026] [Reference Citation Analysis]
25 Polyak A, Kuo A, Sundaram V. Evolution of liver transplant organ allocation policy: Current limitations and future directions. World J Hepatol 2021; 13(8): 830-839 [PMID: 34552690 DOI: 10.4254/wjh.v13.i8.830] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
26 Su WY, Chu NS, Huang JC, Wu PY, Lee WH, Liu YH, Chen SC, Su HM. Low Albumin, Low Bilirubin, and High Alfa-Fetoprotein Are Associated with a Rapid Renal Function Decline in a Large Population Follow-Up Study. J Pers Med 2021;11:781. [PMID: 34442425 DOI: 10.3390/jpm11080781] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
27 Flamm SL, Brown K, Wadei HM, Brown RS Jr, Kugelmas M, Samaniego-Picota M, Burra P, Poordad F, Saab S. The Current Management of Hepatorenal Syndrome-Acute Kidney Injury in the United States and the Potential of Terlipressin. Liver Transpl 2021;27:1191-202. [PMID: 33848394 DOI: 10.1002/lt.26072] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
28 Sangroongruangsri S, Kittrongsiri K, Charatcharoenwitthaya P, Sobhonslidsuk A, Chaikledkaew U. Cost-Utility Analysis of Vasoconstrictors Plus Albumin in the Treatment of Thai Patients with Type 1 Hepatorenal Syndrome. Clinicoecon Outcomes Res 2021;13:703-15. [PMID: 34349534 DOI: 10.2147/CEOR.S317390] [Reference Citation Analysis]
29 Koshy AN, Farouque O, Cailes B, Ko J, Han HC, Weinberg L, Testro A, Robertson M, Teh AW, Lim HS, Gow PJ. Prediction of Perioperative Cardiovascular Events in Liver Transplantation. Transplantation 2021;105:593-601. [PMID: 32413014 DOI: 10.1097/TP.0000000000003306] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
30 Torres-vellojín N, Díaz-duque JC, Toro-molina JL, Muñoz-maya OG. Disfunción renal en el paciente cirrótico. Hepatología 2021. [DOI: 10.52784/27112330.136] [Reference Citation Analysis]
31 Subedi A, Suresh Kumar VC, Sharma Subedi A, Sapkota B. A Review of Hepatorenal Syndrome. Cureus 2021;13:e16084. [PMID: 34367745 DOI: 10.7759/cureus.16084] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
32 Makar M, Reja D, Chouthai A, Kabaria S, Patel AV. The impact of acute kidney injury on mortality and clinical outcomes in patients with alcoholic cirrhosis in the USA. Eur J Gastroenterol Hepatol 2021;33:905-10. [PMID: 32976187 DOI: 10.1097/MEG.0000000000001947] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
33 Mauro E, Garcia-Olveira L, Gadano A. End-stage liver disease: Management of hepatorenal syndrome. Liver Int 2021;41 Suppl 1:119-27. [PMID: 34155791 DOI: 10.1111/liv.14866] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
34 Wang YJ, Li JH, Guan Y, Xie QH, Hao CM, Wang ZX. Diabetes mellitus is a risk factor of acute kidney injury in liver transplantation patients. Hepatobiliary Pancreat Dis Int 2021;20:215-21. [PMID: 33752999 DOI: 10.1016/j.hbpd.2021.02.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
35 Perez I, Bolte FJ, Bigelow W, Dickson Z, Shah NL. Step by Step: Managing the Complications of Cirrhosis. Hepat Med 2021;13:45-57. [PMID: 34079394 DOI: 10.2147/HMER.S278032] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
36 Thongprayoon C, Kaewput W, Petnak T, O'Corragain OA, Boonpheng B, Bathini T, Vallabhajosyula S, Pattharanitima P, Lertjitbanjong P, Qureshi F, Cheungpasitporn W. Impact of Palliative Care Services on Treatment and Resource Utilization for Hepatorenal Syndrome in the United States. Medicines (Basel) 2021;8:21. [PMID: 34065828 DOI: 10.3390/medicines8050021] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
37 Terres AZ, Balbinot RS, Muscope ALF, Longen ML, Schena B, Cini BT, Luis Rost G Jr, Balensiefer JIL, Eberhardt LZ, Balbinot RA, Balbinot SS, Soldera J. Evidence-based protocol for diagnosis and treatment of hepatorenal syndrome is independently associated with lower mortality. Gastroenterol Hepatol 2021:S0210-5705(21)00086-8. [PMID: 33746028 DOI: 10.1016/j.gastrohep.2021.02.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
38 Kubesch A, Peiffer KH, Abramowski H, Dultz G, Graf C, Filmann N, Zeuzem S, Bojunga J, Friedrich-Rust M. The presence of liver cirrhosis is a strong negative predictor of survival for patients admitted to the intensive care unit - Cirrhosis in intensive care patients. Z Gastroenterol 2021;59:657-64. [PMID: 33728617 DOI: 10.1055/a-1401-2387] [Reference Citation Analysis]
39 McAllister S, Lai JC, Copeland TP, Johansen KL, McCulloch CE, Kwong YD, Seth D, Grimes B, Ku E. Renal Recovery and Mortality Risk among Patients with Hepatorenal Syndrome Receiving Chronic Maintenance Dialysis. Kidney360 2021;2:819-27. [PMID: 35373067 DOI: 10.34067/KID.0005182020] [Reference Citation Analysis]
40 Singh J, Dahiya DS, Kichloo A, Singh G, Khoshbin K, Shaka H. Hepatorenal syndrome: a Nationwide Trend Analysis from 2008 to 2018. Annals of Medicine 2021;53:2018-2024. [DOI: 10.1080/07853890.2021.1998595] [Reference Citation Analysis]
41 Rajakumar A, Appuswamy E, Kaliamoorthy I, Rela M. Renal Dysfunction in Cirrhosis: Critical Care Management. Indian J Crit Care Med 2021;25:207-14. [PMID: 33707901 DOI: 10.5005/jp-journals-10071-23721] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
42 Hiruy A, Nelson J, Zori A, Morelli G, Cabrera R, Kamel A. Standardized approach of albumin, midodrine and octreotide on hepatorenal syndrome treatment response rate. Eur J Gastroenterol Hepatol 2021;33:102-6. [PMID: 32243349 DOI: 10.1097/MEG.0000000000001700] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
43 Gallo A, Dedionigi C, Civitelli C, Panzeri A, Corradi C, Squizzato A. Optimal Management of Cirrhotic Ascites: A Review for Internal Medicine Physicians. J Transl Int Med 2020;8:220-36. [PMID: 33511049 DOI: 10.2478/jtim-2020-0035] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
44 Hyun J, Sun Z, Ahmadi AR, Bangru S, Chembazhi UV, Du K, Chen T, Tsukamoto H, Rusyn I, Kalsotra A, Diehl AM. Epithelial splicing regulatory protein 2-mediated alternative splicing reprograms hepatocytes in severe alcoholic hepatitis. J Clin Invest 2020;130:2129-45. [PMID: 31945016 DOI: 10.1172/JCI132691] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 8.3] [Reference Citation Analysis]
45 Velez JCQ. Patients with Hepatorenal Syndrome Should Be Dialyzed? PRO. Kidney360 2021;2:406-9. [PMID: 35369012 DOI: 10.34067/KID.0006952020] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
46 Theodorakopoulos T, Kalafateli M, Kalambokis GN, Samonakis DN, Aggeletopoulou I, Tsolias C, Mantaka A, Tselekouni P, Vourli G, Assimakopoulos SF, Gogos C, Thomopoulos K, Milionis H, Triantos C. Natural history of grade 1 ascites in patients with liver cirrhosis. Ann Gastroenterol 2021;34:93-103. [PMID: 33414628 DOI: 10.20524/aog.2020.0553] [Reference Citation Analysis]
47 Allegretti AS, Solà E, Ginès P. Clinical Application of Kidney Biomarkers in Cirrhosis. American Journal of Kidney Diseases 2020;76:710-9. [DOI: 10.1053/j.ajkd.2020.03.016] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 9.7] [Reference Citation Analysis]
48 Alukal JJ, John S, Thuluvath PJ. Hyponatremia in Cirrhosis: An Update. Am J Gastroenterol 2020;115:1775-85. [PMID: 33156095 DOI: 10.14309/ajg.0000000000000786] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 7.7] [Reference Citation Analysis]
49 Moon AM, Singal AG, Tapper EB. Contemporary Epidemiology of Chronic Liver Disease and Cirrhosis. Clin Gastroenterol Hepatol 2020;18:2650-66. [PMID: 31401364 DOI: 10.1016/j.cgh.2019.07.060] [Cited by in Crossref: 278] [Cited by in F6Publishing: 242] [Article Influence: 92.7] [Reference Citation Analysis]
50 Rey R M, Delgado AF, De Zubiria A, Pinto R, De la Hoz-Valle JA, Pérez-Riveros ED, Ardila G, Sierra-Arango F. Prevalence and short-term outcome of hepatorenal syndrome: A 9-year experience in a high-complexity hospital in Colombia. PLoS One 2020;15:e0239834. [PMID: 33079947 DOI: 10.1371/journal.pone.0239834] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
51 Liu PMF, de Carvalho ST, Fradico PF, Cazumbá MLB, Campos RGB, Simões E Silva AC. Hepatorenal syndrome in children: a review. Pediatr Nephrol 2021;36:2203-15. [PMID: 33001296 DOI: 10.1007/s00467-020-04762-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 2.3] [Reference Citation Analysis]
52 Simonetto DA, Gines P, Kamath PS. Hepatorenal syndrome: pathophysiology, diagnosis, and management.BMJ. 2020;370:m2687. [PMID: 32928750 DOI: 10.1136/bmj.m2687] [Cited by in Crossref: 58] [Cited by in F6Publishing: 60] [Article Influence: 19.3] [Reference Citation Analysis]
53 Wu PS, Wang YW, Tai CC, Hsieh YC, Lee PC, Huang CC, Huang YH, Hou MC, Lin HC, Lee KC. Early echocardiographic signs of diastolic dysfunction predict acute kidney injury in cirrhotic patients. J Chin Med Assoc 2020;83:984-90. [PMID: 32889984 DOI: 10.1097/JCMA.0000000000000422] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
54 Smith RE, Friedman AD, Murchison JA, Tanner SB, Smith PA, Dollar BT. Acute Life-Threatening Complications of Portal Hypertension: a Review of Pathophysiology, Incidence, Management, and Cost. SN Compr Clin Med 2020;2:1628-1645. [DOI: 10.1007/s42399-020-00435-5] [Reference Citation Analysis]
55 Fida S, Khurshid SMS, Mansoor H. Frequency of Hepatorenal Syndrome Among Patients With Cirrhosis and Outcome After Treatment. Cureus 2020;12:e10016. [PMID: 32983712 DOI: 10.7759/cureus.10016] [Reference Citation Analysis]
56 Tariq R, Singal AK. Management of Hepatorenal Syndrome: A Review. J Clin Transl Hepatol 2020;8:192-9. [PMID: 32832400 DOI: 10.14218/JCTH.2020.00011] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
57 Wu YH, Wu CY, Cheng CY, Tsai SF. Severe hyperbilirubinemia is associated with higher risk of contrast-related acute kidney injury following contrast-enhanced computed tomography. PLoS One 2020;15:e0231264. [PMID: 32294106 DOI: 10.1371/journal.pone.0231264] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
58 Trivedi PS, Brown MA, Rochon PJ, Ryu RK, Johnson DT. Gender Disparity in Inpatient Mortality After Transjugular Intrahepatic Portosystemic Shunt Creation in Patients Admitted With Hepatorenal Syndrome: A Nationwide Study. Journal of the American College of Radiology 2020;17:231-7. [DOI: 10.1016/j.jacr.2019.08.020] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
59 Zimmerman MA, Schiller J, Selim M, Kim J, Hong JC. Management of Renal Failure in the Liver Transplant Patient. Curr Transpl Rep 2019;6:338-343. [DOI: 10.1007/s40472-019-00259-w] [Reference Citation Analysis]
60 Facciorusso A. Hepatorenal Syndrome Type 1: Current Challenges And Future Prospects.Ther Clin Risk Manag. 2019;15:1383-1391. [PMID: 31819465 DOI: 10.2147/TCRM.S205328] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
61 Velez JCQ, Therapondos G, Juncos LA. Reappraising the spectrum of AKI and hepatorenal syndrome in patients with cirrhosis.Nat Rev Nephrol. 2020;16:137-155. [PMID: 31723234 DOI: 10.1038/s41581-019-0218-4] [Cited by in Crossref: 44] [Cited by in F6Publishing: 47] [Article Influence: 11.0] [Reference Citation Analysis]
62 Hermert D, Martin IV, Reiss LK, Liu X, Breitkopf DM, Reimer KC, Alidousty C, Rauen T, Floege J, Ostendorf T, Weiskirchen R, Raffetseder U. The nucleic acid binding protein YB-1-controlled expression of CXCL-1 modulates kidney damage in liver fibrosis. Kidney Int 2020;97:741-52. [PMID: 32061437 DOI: 10.1016/j.kint.2019.10.024] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
63 Adebayo D, Neong SF, Wong F. Ascites and Hepatorenal Syndrome. Clin Liver Dis 2019;23:659-82. [PMID: 31563217 DOI: 10.1016/j.cld.2019.06.002] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
64 Barnes A, Woodman RJ, Kleinig P, Briffa M, To T, Wigg AJ. Early palliative care referral in patients with end stage liver disease is associated with reduced resource utilisation. J Gastroenterol Hepatol 2019. [PMID: 31613397 DOI: 10.1111/jgh.14877] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
65 Wang L, Long Y, Li KX, Xu GS. Pharmacological treatment of hepatorenal syndrome: a network meta-analysis.Gastroenterol Rep (Oxf). 2020;8:111-118. [PMID: 32280470 DOI: 10.1093/gastro/goz043] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
66 Schiavon LL, Ejima FH, Menezes MR, Bittencourt PL, Moreira AM, Farias AQ, Chagas AL, Assis AM, Mattos ÂZ, Salomão BC, Terra C, Martins FPB, Carnevale FC, Rezende GFDM, Paulo GA, Pereira GHS, Leal Filho JMDM, Meneses J, Costa LSND, Carneiro MV, Álvares-DA-Silva MR, Soares MVA, Pereira OI, Ximenes RO, Durante RFS, Ferreira VA, Lima VM; Members of the Pannel of the 1st Joint Meeting of the SBH, SOBED and SOBRICE. RECOMMENDATIONS FOR INVASIVE PROCEDURES IN PATIENTS WITH DISEASES OF THE LIVER AND BILIARY TRACT: REPORT OF A JOINT MEETING OF THE BRAZILIAN SOCIETY OF HEPATOLOGY (SBH), BRAZILIAN SOCIETY OF DIGESTIVE ENDOSCOPY (SOBED) AND BRAZILIAN SOCIETY OF INTERVENTIONAL RADIOLOGY AND ENDOVASCULAR SURGERY (SOBRICE). Arq Gastroenterol 2019;56:213-31. [PMID: 31460590 DOI: 10.1590/S0004-2803.201900000-42] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
67 Koola JD, Chen G, Malin BA, Fabbri D, Siew ED, Ho SB, Patterson OV, Matheny ME. A clinical risk prediction model to identify patients with hepatorenal syndrome at hospital admission. Int J Clin Pract. 2019;73:e13393. [PMID: 31347754 DOI: 10.1111/ijcp.13393] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
68 Bhatti HW, Tahir U, Chaudhary NA, Bhatti S, Hafeez M, Rizvi ZA. Factors associated with renal dysfunction in hepatitis C-related cirrhosis and its correlation with Child-Pugh score. BMJ Open Gastroenterol 2019;6:e000286. [PMID: 31275583 DOI: 10.1136/bmjgast-2019-000286] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
69 Runken MC, Caraceni P, Fernandez J, Zipprich A, Carlton R, Bunke M. The cost-effectiveness of albumin in the treatment of decompensated cirrhosis in Germany, Italy, and Spain. Health Econ Rev 2019;9:22. [PMID: 31278624 DOI: 10.1186/s13561-019-0237-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
70 Nevens F, Bittencourt PL, Coenraad MJ, Ding H, Hou MC, Laterre PF, Mendizabal M, Ortiz-Olvera NX, Vorobioff JD, Zhang W, Angeli P. Recommendations on the Diagnosis and Initial Management of Acute Variceal Bleeding and Hepatorenal Syndrome in Patients with Cirrhosis. Dig Dis Sci 2019;64:1419-31. [PMID: 30684079 DOI: 10.1007/s10620-018-5448-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
71 Francoz C, Sola E. Assessment of renal function in cirrhosis: Sarcopenia, gender and ethnicity matter. J Hepatol 2019;70:828-30. [PMID: 30833013 DOI: 10.1016/j.jhep.2019.02.004] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
72 Attar B. Approach to Hyponatremia in Cirrhosis. Clin Liver Dis (Hoboken) 2019;13:98-101. [PMID: 31061701 DOI: 10.1002/cld.790] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
73 Varajic B, Cavallazzi R, Mann J, Furmanek S, Guardiola J, Saad M. High versus low mean arterial pressures in hepatorenal syndrome: A randomized controlled pilot trial. J Crit Care 2019;52:186-92. [PMID: 31096099 DOI: 10.1016/j.jcrc.2019.04.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
74 Shenoda B, Boselli J. Vascular syndromes in liver cirrhosis. Clin J Gastroenterol 2019;12:387-97. [PMID: 30980261 DOI: 10.1007/s12328-019-00956-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
75 Dong V, Karvellas CJ. Acute-on-chronic liver failure: Objective admission and support criteria in the intensive care unit. JHEP Rep 2019;1:44-52. [PMID: 32039351 DOI: 10.1016/j.jhepr.2019.02.005] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
76 Jamil K, Huang X, Lovelace B, Pham AT, Lodaya K, Wan G. The burden of illness of hepatorenal syndrome (HRS) in the United States: a retrospective analysis of electronic health records. J Med Econ 2019;22:421-9. [PMID: 30724682 DOI: 10.1080/13696998.2019.1580201] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 4.5] [Reference Citation Analysis]
77 Xu J, Xia Y, Li S, Cheng X, Hu S, Gao Y, Zhou X, Wang G, Zheng Q. A retrospective pilot study to examine the potential of aspartate aminotransferase to alanine aminotransferase ratio as a predictor of postoperative acute kidney injury in patients with hepatocellular carcinoma. Ann Clin Biochem 2019;56:357-66. [PMID: 30453754 DOI: 10.1177/0004563218817797] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
78 Nguyen-Tat M, Jäger J, Rey JW, Nagel M, Labenz C, Wörns MA, Galle PR, Marquardt JU. Terlipressin and albumin combination treatment in patients with hepatorenal syndrome type 2. United European Gastroenterol J 2019;7:529-37. [PMID: 31065370 DOI: 10.1177/2050640619825719] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
79 Myers SP, Kulkarni SS, Malik SM, Tevar AD, Neal MD. Hernia Management in Cirrhosis: Risk Assessment, Operative Approach, and Perioperative Care. J Surg Res 2019;235:1-7. [PMID: 30691782 DOI: 10.1016/j.jss.2018.09.052] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
80 Piano S, Tonon M, Angeli P. Pathophysiology and Management of the Hepatorenal Syndrome. Critical Care Nephrology 2019. [DOI: 10.1016/b978-0-323-44942-7.00128-x] [Reference Citation Analysis]
81 Piano S, Angeli P. Acute Kidney Injury and Hepatorenal Syndrome. Critical Care for Potential Liver Transplant Candidates 2019. [DOI: 10.1007/978-3-319-92934-7_9] [Reference Citation Analysis]
82 Ando Y, Ahn J. Hepatorenal Syndrome. Liver Disease 2019. [DOI: 10.1007/978-3-319-98506-0_5] [Reference Citation Analysis]
83 Song J, Zhu L, Zhu C, Hu J, Sun Z, Xu X, Xin M, Zhang Q, Zhang D, Shang J, Huang J, Xu D. Main Complications of AECHB and Severe Hepatitis B (Liver Failure). Acute Exacerbation of Chronic Hepatitis B 2019. [DOI: 10.1007/978-94-024-1603-9_2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
84 Myers SP, Malik SM, Tevar AD, Neal MD. Herniorrhaphy in Cirrhosis: Operative Approach and Timing. The SAGES Manual of Hernia Surgery 2019. [DOI: 10.1007/978-3-319-78411-3_47] [Reference Citation Analysis]
85 Yang SM, Choi SN, Yu JH, Yoon HK, Kim WH, Jung CW, Suh KS, Lee KH. Intraoperative hyponatremia is an independent predictor of one-year mortality after liver transplantation. Sci Rep 2018;8:18023. [PMID: 30575797 DOI: 10.1038/s41598-018-37006-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
86 Neong SF, Adebayo D, Wong F. An update on the pathogenesis and clinical management of cirrhosis with refractory ascites. Expert Rev Gastroenterol Hepatol 2019;13:293-305. [PMID: 30791777 DOI: 10.1080/17474124.2018.1555469] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 3.2] [Reference Citation Analysis]
87 Leise M, Cárdenas A. Hyponatremia in Cirrhosis: Implications for Liver Transplantation. Liver Transpl 2018;24:1612-21. [PMID: 30129266 DOI: 10.1002/lt.25327] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 3.4] [Reference Citation Analysis]
88 Flamm SL, Mullen KD, Heimanson Z, Sanyal AJ. Rifaximin has the potential to prevent complications of cirrhosis. Therap Adv Gastroenterol 2018;11:1756284818800307. [PMID: 30283499 DOI: 10.1177/1756284818800307] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
89 Bernardi M, Zaccherini G. Approach and management of dysnatremias in cirrhosis. Hepatol Int. 2018;12:487-499. [PMID: 30203382 DOI: 10.1007/s12072-018-9894-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
90 Terra C, Mattos ÂZD, Pereira G, Farias AQ, Kondo M, Mattos AAD, Medeiros Filho JEMD, Strauss E, Dutra FRD, Mazza M, Lopes EP, Pereira TS, Schiavon LL, Carvalho Filho RJD, Fagundes C, Bittencourt PL. RECOMMENDATIONS OF THE BRAZILIAN SOCIETY OF HEPATOLOGY FOR THE MANAGEMENT OF ACUTE KIDNEY INJURY IN PATIENTS WITH CIRRHOSIS. Arq Gastroenterol 2018;55:314-20. [DOI: 10.1590/s0004-2803.201800000-71] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
91 Weinmann-menke J, Weinmann A, Lutz J. Hepatorenales Syndrom. Nephrologe 2018;13:277-289. [DOI: 10.1007/s11560-018-0264-0] [Reference Citation Analysis]
92 Garcia-tsao G. Ascites. Sherlock's Diseases of the Liver and Biliary System 2018. [DOI: 10.1002/9781119237662.ch9] [Reference Citation Analysis]
93 Kalambokis GN, Tsiakas I, Christaki M, Koustousi C, Christou L, Baltayiannis G, Christodoulou D. Systemic hemodynamic response to terlipressin predicts development of hepatorenal syndrome and survival in advanced cirrhosis. Eur J Gastroenterol Hepatol 2018;30:659-67. [PMID: 29432366 DOI: 10.1097/MEG.0000000000001088] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
94 Shetty S, Nagaraju SP, Shenoy S, Attur RP, Rangaswamy D, Rao IR, Mateti UV, Parthasarathy R. Acute kidney injury in patients with cirrhosis of liver: Clinical profile and predictors of outcome. Indian J Gastroenterol 2018;37:248-54. [PMID: 30014435 DOI: 10.1007/s12664-018-0867-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
95 Koola JD, Davis SE, Al-Nimri O, Parr SK, Fabbri D, Malin BA, Ho SB, Matheny ME. Development of an automated phenotyping algorithm for hepatorenal syndrome. J Biomed Inform 2018;80:87-95. [PMID: 29530803 DOI: 10.1016/j.jbi.2018.03.001] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 4.2] [Reference Citation Analysis]
96 Said MM, Azab SS, Saeed NM, El-Demerdash E. Antifibrotic Mechanism of Pinocembrin: Impact on Oxidative Stress, Inflammation and TGF-β /Smad Inhibition in Rats. Ann Hepatol 2018;17:307-17. [PMID: 29469035 DOI: 10.5604/01.3001.0010.8661] [Cited by in Crossref: 11] [Cited by in F6Publishing: 19] [Article Influence: 2.2] [Reference Citation Analysis]
97 Stine JG, Wang J, Cornella SL, Behm BW, Henry Z, Shah NL, Caldwell SH, Northup PG. Treatment of Type-1 Hepatorenal Syndrome with Pentoxifylline: A Randomized Placebo Controlled Clinical Trial. Ann Hepatol 2018;17:300-6. [PMID: 29469046 DOI: 10.5604/01.3001.0010.8660] [Cited by in Crossref: 16] [Cited by in F6Publishing: 20] [Article Influence: 3.2] [Reference Citation Analysis]
98 Kramer L, Bauer E, Gendo A, Madl C, Gangl A. Influence of Hydroxy Ethyl Starch Infusion on Serum Bilirubin Levels in Cirrhotic Patients Treated with Artificial Liver Support. Int J Artif Organs 2002;25:918-22. [DOI: 10.1177/039139880202501004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
99 Chen Y, Wu Z, He J, Yu J, Yang S, Zhang Y, Du W, Cao H, Li L. The Curative Effect of ALSS on 1-month Mortality in AoCLF Patients after 72 to 120 Hours. Int J Artif Organs 2007;30:906-14. [DOI: 10.1177/039139880703001008] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
100 Fabrizi F, Dixit V, Messa P, Martin P. Terlipressin for Hepatorenal Syndrome: A Meta-Analysis of Randomized Trials. Int J Artif Organs 2009;32:133-40. [DOI: 10.1177/039139880903200303] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 8.2] [Reference Citation Analysis]
101 Diaz GC, Chow J, Renz JF. Combined Solid Organ Transplantation Involving the Liver. Liver Anesthesiology and Critical Care Medicine 2018. [DOI: 10.1007/978-3-319-64298-7_19] [Reference Citation Analysis]
102 Berl T, Schrier RW. Vasopressin Antagonists in Physiology and Disease. Textbook of Nephro-Endocrinology 2018. [DOI: 10.1016/b978-0-12-803247-3.00007-6] [Reference Citation Analysis]
103 Belcher JM, Parikh CR. Acute Kidney Injury and Liver Disease: Incidence, Pathophysiology, Prevention/Treatment, and Outcomes. Core Concepts in Acute Kidney Injury 2018. [DOI: 10.1007/978-1-4939-8628-6_7] [Reference Citation Analysis]
104 Colle I, Laterre PF. Hepatorenal syndrome: the clinical impact of vasoactive therapy. Expert Rev Gastroenterol Hepatol. 2018;12:173-188. [PMID: 29258378 DOI: 10.1080/17474124.2018.1417034] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
105 Majc D, Tepes B. The Impact of Outpatient Clinical Care on the Survival and Hospitalisation Rate in Patients with Alcoholic Liver Cirrhosis. Radiol Oncol 2018;52:75-82. [PMID: 29520208 DOI: 10.1515/raon-2017-0056] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
106 Kamal F, Khan MA, Khan Z, Cholankeril G, Hammad TA, Lee WM, Ahmed A, Waters B, Howden CW, Nair S, Satapathy SK. Rifaximin for the prevention of spontaneous bacterial peritonitis and hepatorenal syndrome in cirrhosis: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol 2017;29:1109-17. [PMID: 28763340 DOI: 10.1097/MEG.0000000000000940] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
107 Israelsen M, Krag A, Allegretti AS, Jovani M, Goldin AH, Winter RW, Gluud LL. Terlipressin vs other vasoactive drugs for hepatorenal syndrome. Cochrane Database Syst Rev. 2017;9:CD011532. [PMID: 28953318 DOI: 10.1002/14651858.cd011532.pub2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 24] [Article Influence: 2.5] [Reference Citation Analysis]
108 Sridharan K, Sivaramakrishnan G. Vasoactive Agents for Hepatorenal Syndrome: A Mixed Treatment Comparison Network Meta-Analysis and Trial Sequential Analysis of Randomized Clinical Trials. J Gen Intern Med. 2018;33:97-102. [PMID: 28924736 DOI: 10.1007/s11606-017-4178-8] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
109 Scheiner B, Parada-Rodriguez D, Bucsics T, Schwabl P, Mandorfer M, Pfisterer N, Riedl F, Sieghart W, Ferlitsch A, Trauner M, Peck-Radosavljevic M, Reiberger T. Non-selective beta-blocker treatment does not impact on kidney function in cirrhotic patients with varices. Scand J Gastroenterol 2017;52:1008-15. [PMID: 28532189 DOI: 10.1080/00365521.2017.1329456] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
110 Singh N, Ahmadzadeh S, Shokouh-Amiri H, Qazi YA, Sequeira A, Samant H, McMillan R, Zibari GB. Kidney outcomes in patients with liver cirrhosis and chronic kidney disease receiving an orthotopic liver transplant alone. Clin Transplant. 2017;31. [PMID: 28504869 DOI: 10.1111/ctr.13008] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
111 Allegretti AS, Israelsen M, Krag A, Jovani M, Goldin AH, Schulman AR, Winter RW, Gluud LL. Terlipressin versus placebo or no intervention for people with cirrhosis and hepatorenal syndrome. Cochrane Database Syst Rev 2017;6:CD005162. [PMID: 29943803 DOI: 10.1002/14651858.CD005162.pub4] [Cited by in Crossref: 17] [Cited by in F6Publishing: 23] [Article Influence: 2.8] [Reference Citation Analysis]
112 Flechner SM. Simultaneous Liver-Kidney Transplantation: What are Our Obligations to the Kidney Only Recipient? Curr Transpl Rep 2017;4:110-5. [DOI: 10.1007/s40472-017-0150-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
113 Kao CC, Yang JY, Chen L, Chao CT, Peng YS, Chiang CK, Huang JW, Hung KY. Factors associated with poor outcomes of continuous renal replacement therapy. PLoS One. 2017;12:e0177759. [PMID: 28542272 DOI: 10.1371/journal.pone.0177759] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 3.5] [Reference Citation Analysis]
114 Foshat M, Ruff HM, Fischer WG, Beach RE, Fowler MR, Ju H, Aronson JF, Afrouzian M. Bile Cast Nephropathy in Cirrhotic Patients: Effects of Chronic Hyperbilirubinemia. Am J Clin Pathol 2017;147:525-35. [PMID: 28398539 DOI: 10.1093/ajcp/aqx030] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 2.5] [Reference Citation Analysis]
115 Fabrizi F, Messa P. Challenges in Renal Failure Treatment Before Liver Transplant. Clin Liver Dis 2017;21:303-19. [PMID: 28364815 DOI: 10.1016/j.cld.2016.12.005] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
116 Altaf. Determine the Frequency of Hepatorenal Syndrome in Patients with Cirrhosis Associated With Hepatitis C. ICPJL 2017;4. [DOI: 10.15406/icpjl.2017.04.00105] [Reference Citation Analysis]
117 Bucsics T, Krones E. Renal dysfunction in cirrhosis: acute kidney injury and the hepatorenal syndrome. Gastroenterol Rep (Oxf). 2017;5:127-137. [PMID: 28533910 DOI: 10.1093/gastro/gox009] [Cited by in Crossref: 45] [Cited by in F6Publishing: 47] [Article Influence: 7.5] [Reference Citation Analysis]
118 Walayat S, Martin D, Patel J, Ahmed U, N Asghar M, Pai AU, Dhillon S. Role of albumin in cirrhosis: from a hospitalist's perspective. J Community Hosp Intern Med Perspect. 2017;7:8-14. [PMID: 28634518 DOI: 10.1080/20009666.2017.1302704] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 2.2] [Reference Citation Analysis]
119 Yap DY, Seto WK, Fung J, Chok SH, Chan SC, Chan GC, Yuen MF, Chan TM. Serum and urinary biomarkers that predict hepatorenal syndrome in patients with advanced cirrhosis. Dig Liver Dis 2017;49:202-6. [PMID: 27876501 DOI: 10.1016/j.dld.2016.11.001] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
120 Stenglein J. Anesthesia for Liver Transplantation. Anesthesiology 2017. [DOI: 10.1007/978-3-319-50141-3_28] [Reference Citation Analysis]
121 Malespin M, Tsang R. What Do Abnormal Liver Tests Mean? Liver Disorders 2017. [DOI: 10.1007/978-3-319-30103-7_1] [Reference Citation Analysis]
122 Paternostro R, Reiberger T, Mandorfer M, Schwarzer R, Schwabl P, Bota S, Ferlitsch M, Trauner M, Peck-Radosavljevic M, Ferlitsch A. Plasma renin concentration represents an independent risk factor for mortality and is associated with liver dysfunction in patients with cirrhosis. J Gastroenterol Hepatol 2017;32:184-90. [PMID: 27164413 DOI: 10.1111/jgh.13439] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
123 Yeboah MM. Hepatorenal Syndrome. Liver Disorders 2017. [DOI: 10.1007/978-3-319-30103-7_32] [Reference Citation Analysis]
124 Segarra G, Cortina B, Mauricio MD, Novella S, Lluch P, Navarrete-Navarro J, Noguera I, Medina P. Effects of asymmetric dimethylarginine on renal arteries in portal hypertension and cirrhosis. World J Gastroenterol 2016; 22(48): 10545-10556 [PMID: 28082806 DOI: 10.3748/wjg.v22.i48.10545] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
125 Annamalai A, Harada MY, Chen M, Tran T, Ko A, Ley EJ, Nuno M, Klein A, Nissen N, Noureddin M. Predictors of Mortality in the Critically Ill Cirrhotic Patient: Is the Model for End-Stage Liver Disease Enough? J Am Coll Surg 2017;224:276-82. [PMID: 27887981 DOI: 10.1016/j.jamcollsurg.2016.11.005] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
126 Bucsics T, Schwabl P, Mandorfer M, Bota S, Sieghart W, Ferlitsch A, Trauner M, Reiberger T, Peck-Radosavljevic M. The trigger matters - outcome of hepatorenal syndrome vs. specifically triggered acute kidney injury in cirrhotic patients with ascites. Liver Int 2016;36:1649-56. [PMID: 27169985 DOI: 10.1111/liv.13160] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
127 Arab JP, Claro JC, Arancibia JP, Contreras J, Gómez F, Muñoz C, Nazal L, Roessler E, Wolff R, Arrese M, Benítez C. Therapeutic alternatives for the treatment of type 1 hepatorenal syndrome: A Delphi technique-based consensus. World J Hepatol 2016; 8(25): 1075-1086 [PMID: 27660674 DOI: 10.4254/wjh.v8.i25.1075] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
128 Enescu A, Petrescu F, Mitruţ P, Petrescu IO, Pădureanu V, Enescu AŞ. Hepatorenal Syndrome: Diagnosis and Treatment - newsreel. Rom J Intern Med 2016;54:143-50. [PMID: 27658161 DOI: 10.1515/rjim-2016-0024] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
129 Kane W. It is reasonable to treat patients with type 1 hepatorenal syndrome with midodrine and octreotide. Clin Res Pract 2016;2. [DOI: 10.22237/crp/1469036125] [Reference Citation Analysis]
130 Shah N, Silva RG, Kowalski A, Desai C, Lerma E. Hepatorenal syndrome. Dis Mon. 2016;62:364-375. [PMID: 27372112 DOI: 10.1016/j.disamonth.2016.05.009] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
131 Trivedi PS, Rochon PJ, Durham JD, Ryu RK. National Trends and Outcomes of Transjugular Intrahepatic Portosystemic Shunt Creation Using the Nationwide Inpatient Sample. Journal of Vascular and Interventional Radiology 2016;27:838-45. [DOI: 10.1016/j.jvir.2015.12.013] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
132 Carl DE, Ghosh SS, Gehr TW, Abbate A, Toldo S, Sanyal AJ. A model of acute kidney injury in mice with cirrhosis and infection. Liver Int 2016;36:865-73. [PMID: 26583566 DOI: 10.1111/liv.13023] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
133 Maiwall R, Kumar S, Sharma MK, Wani Z, Ozukum M, Sarin SK. Prevalence and prognostic significance of hyperkalemia in hospitalized patients with cirrhosis. J Gastroenterol Hepatol 2016;31:988-94. [PMID: 26598065 DOI: 10.1111/jgh.13243] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
134 Tapper EB, Bonder A, Cardenas A. Preventing and Treating Acute Kidney Injury Among Hospitalized Patients with Cirrhosis and Ascites: A Narrative Review. Am J Med 2016;129:461-7. [PMID: 26724589 DOI: 10.1016/j.amjmed.2015.12.006] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
135 Lizaola B, Bonder A, Tapper EB, Mendez-bocanegra A, Cardenas A. The Changing Role of Sodium Management in Cirrhosis. Curr Treat Options Gastro 2016;14:274-84. [DOI: 10.1007/s11938-016-0094-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
136 Allegretti AS, Ortiz G, Cui J, Wenger J, Bhan I, Chung RT, Thadhani RI, Irani Z. Changes in Kidney Function After Transjugular Intrahepatic Portosystemic Shunts Versus Large-Volume Paracentesis in Cirrhosis: A Matched Cohort Analysis. Am J Kidney Dis 2016;68:381-91. [PMID: 26994685 DOI: 10.1053/j.ajkd.2016.02.041] [Cited by in Crossref: 32] [Cited by in F6Publishing: 35] [Article Influence: 4.6] [Reference Citation Analysis]
137 Rathi S, Dhiman RK. Hepatobiliary Quiz Answers-17 (2016). J Clin Exp Hepatol 2016;6:73-6. [PMID: 27194902 DOI: 10.1016/j.jceh.2016.03.005] [Reference Citation Analysis]
138 Solà E, Huelin P, Ginès P. The Management of Hyponatremia in Cirrhosis: Should it Be Pharmacologic? Curr Hepatology Rep 2016;15:53-59. [DOI: 10.1007/s11901-016-0293-y] [Reference Citation Analysis]
139 Assem M, Elsabaawy M, Abdelrashed M, Elemam S, Khodeer S, Hamed W, Abdelaziz A, El-Azab G. Efficacy and safety of alternating norfloxacin and rifaximin as primary prophylaxis for spontaneous bacterial peritonitis in cirrhotic ascites: a prospective randomized open-label comparative multicenter study. Hepatol Int. 2016;10:377-385. [PMID: 26660707 DOI: 10.1007/s12072-015-9688-z] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 4.4] [Reference Citation Analysis]
140 Srivastava S, Shalimar, Vishnubhatla S, Prakash S, Sharma H, Thakur B, Acharya SK. Randomized Controlled Trial Comparing the Efficacy of Terlipressin and Albumin with a Combination of Concurrent Dopamine, Furosemide, and Albumin in Hepatorenal Syndrome. J Clin Exp Hepatol 2015;5:276-85. [PMID: 26900268 DOI: 10.1016/j.jceh.2015.08.003] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 3.8] [Reference Citation Analysis]
141 Adachi M, Tanaka A, Aiso M, Takamori Y, Takikawa H. Benefit of cystatin C in evaluation of renal function and prediction of survival in patients with cirrhosis. Hepatol Res 2015;45:1299-306. [PMID: 25704216 DOI: 10.1111/hepr.12508] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
142 Piano S, Angeli P. Dopamine and Furosemide for the Treatment of Hepatorenal Syndrome: A Reappraisal or Just Smoke and Mirrors? J Clin Exp Hepatol 2015;5:273-5. [PMID: 26900267 DOI: 10.1016/j.jceh.2015.12.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
143 Garcia-tsao G. Ascites and Its Complications. Yamada' s Textbook of Gastroenterology 2015. [DOI: 10.1002/9781118512074.ch106] [Reference Citation Analysis]
144 Velez JC, Kadian M, Taburyanskaya M, Bohm NM, Delay TA, Karakala N, Rockey DC, Nietert PJ, Goodwin AJ, Whelan TP. Hepatorenal Acute Kidney Injury and the Importance of Raising Mean Arterial Pressure. Nephron 2015;131:191-201. [PMID: 26485256 DOI: 10.1159/000441151] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 2.5] [Reference Citation Analysis]
145 Maiwall R, Sarin SK, Moreau R. Acute kidney injury in acute on chronic liver failure. Hepatol Int 2016;10:245-57. [DOI: 10.1007/s12072-015-9652-y] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 2.5] [Reference Citation Analysis]
146 Bittencourt PL, Farias AQ, Terra C. Renal failure in cirrhosis: Emerging concepts. World J Hepatol 2015; 7(21): 2336-2343 [PMID: 26413223 DOI: 10.4254/wjh.v7.i21.2336] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
147 Kerbert AJ, Verbeke L, Chiang FW, Laleman W, van der Reijden JJ, van Duijn W, Nevens F, Wolterbeek R, van Hoek B, Verspaget HW, Coenraad MJ. Copeptin as an Indicator of Hemodynamic Derangement and Prognosis in Liver Cirrhosis. PLoS One 2015;10:e0138264. [PMID: 26378453 DOI: 10.1371/journal.pone.0138264] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
148 Russ KB, Stevens TM, Singal AK. Acute Kidney Injury in Patients with Cirrhosis. J Clin Transl Hepatol. 2015;3:195-204. [PMID: 26623266 DOI: 10.14218/jcth.2015.00015] [Cited by in Crossref: 60] [Cited by in F6Publishing: 63] [Article Influence: 7.5] [Reference Citation Analysis]
149 Aggarwal HK, Jain D, Singla S, Jain P. Assessment of renal functions in patients of chronic liver disease. Ren Fail 2015;37:1457-63. [PMID: 26338024 DOI: 10.3109/0886022X.2015.1077318] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
150 Saxena V, Lai JC. Kidney Failure and Liver Allocation: Current Practices and Potential Improvements. Adv Chronic Kidney Dis 2015;22:391-8. [PMID: 26311601 DOI: 10.1053/j.ackd.2015.05.002] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
151 Al-khafaji A, Nadim MK, Kellum JA. Hepatorenal Disorders. Chest 2015;148:550-8. [DOI: 10.1378/chest.14-1925] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
152 Cavallin M, Kamath PS, Merli M, Fasolato S, Toniutto P, Salerno F, Bernardi M, Romanelli RG, Colletta C, Salinas F, Di Giacomo A, Ridola L, Fornasiere E, Caraceni P, Morando F, Piano S, Gatta A, Angeli P; Italian Association for the Study of the Liver Study Group on Hepatorenal Syndrome. Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: A randomized trial. Hepatology 2015;62:567-74. [PMID: 25644760 DOI: 10.1002/hep.27709] [Cited by in Crossref: 211] [Cited by in F6Publishing: 180] [Article Influence: 26.4] [Reference Citation Analysis]
153 Romano TG, Vieira Junior JM. Do Biliary Salts Have Role on Acute Kidney Injury Development? J Clin Med Res 2015;7:667-71. [PMID: 26251679 DOI: 10.14740/jocmr2261w] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
154 Allegretti AS, Ortiz G, Wenger J, Deferio JJ, Wibecan J, Kalim S, Tamez H, Chung RT, Karumanchi SA, Thadhani RI. Prognosis of Acute Kidney Injury and Hepatorenal Syndrome in Patients with Cirrhosis: A Prospective Cohort Study. Int J Nephrol. 2015;2015:108139. [PMID: 26266048 DOI: 10.1155/2015/108139] [Cited by in Crossref: 42] [Cited by in F6Publishing: 45] [Article Influence: 5.3] [Reference Citation Analysis]
155 Shah NL, Banaei YP, Hojnowski KL, Cornella SL. Management options in decompensated cirrhosis. Hepat Med 2015;7:43-50. [PMID: 26203291 DOI: 10.2147/HMER.S62463] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
156 Potosek J, Curry M, Buss M, Chittenden E. Integration of palliative care in end-stage liver disease and liver transplantation. J Palliat Med. 2014;17:1271-1277. [PMID: 25390468 DOI: 10.1089/jpm.2013.0167] [Cited by in Crossref: 74] [Cited by in F6Publishing: 81] [Article Influence: 9.3] [Reference Citation Analysis]
157 Hassan EA, Abdel Rehim AS. Creatinine modified Child-Turcotte-Pugh and integrated model of end-stage liver disease scores as predictors of spontaneous bacterial peritonitis-related in-hospital mortality: Applicable or not. J Gastroenterol Hepatol 2015;30:1205-10. [PMID: 25678363 DOI: 10.1111/jgh.12918] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
158 Tong W, Hurley S, Hayashi PH. Reconsidering hepatorenal syndrome: Throw in the towel? Not so fast! Postgraduate Medicine 2015;116:15-24. [DOI: 10.3810/pgm.2004.12.1625] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
159 Zhang Z, Maddukuri G, Jaipaul N, Cai CX. Role of renal replacement therapy in patients with type 1 hepatorenal syndrome receiving combination treatment of vasoconstrictor plus albumin. J Crit Care. 2015;30:969-974. [PMID: 26051980 DOI: 10.1016/j.jcrc.2015.05.006] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 4.1] [Reference Citation Analysis]
160 Didsbury MS, Mackie FE, Kennedy SE. A systematic review of acute kidney injury in pediatric allogeneic hematopoietic stem cell recipients. Pediatr Transplant 2015;19:460-70. [PMID: 25963934 DOI: 10.1111/petr.12483] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 3.6] [Reference Citation Analysis]
161 Pedersen JS, Bendtsen F, Møller S. Management of cirrhotic ascites. Ther Adv Chronic Dis 2015;6:124-37. [PMID: 25954497 DOI: 10.1177/2040622315580069] [Cited by in Crossref: 34] [Cited by in F6Publishing: 38] [Article Influence: 4.3] [Reference Citation Analysis]
162 Dundar HZ, Yılmazlar T. Management of hepatorenal syndrome. World J Nephrol 2015; 4(2): 277-286 [PMID: 25949942 DOI: 10.5527/wjn.v4.i2.277] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
163 Cai CX, Maddukuri G, Jaipaul N, Zhang Z. A Treat-to-Target Concept to Guide the Medical Management of Hepatorenal Syndrome. Dig Dis Sci 2015;60:1474-81. [PMID: 25532500 DOI: 10.1007/s10620-014-3483-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
164 Low G, Owen NE, Joubert I, Patterson AJ, Graves MJ, Alexander GJ, Lomas DJ. Magnetic resonance elastography in the detection of hepatorenal syndrome in patients with cirrhosis and ascites. Eur Radiol. 2015;25:2851-2858. [PMID: 25903705 DOI: 10.1007/s00330-015-3723-2] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
165 Heidemann J, Bartels C, Berssenbrügge C, Schmidt H, Meister T. Hepatorenal syndrome: outcome of response to therapy and predictors of survival. Gastroenterol Res Pract. 2015;2015:457613. [PMID: 25983746 DOI: 10.1155/2015/457613] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
166 Janicko M, Veseliny E, Senajova G, Jarcuska P. Predictors of hepatorenal syndrome in alcoholic liver cirrhosis. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2015;159:661-5. [PMID: 25820623 DOI: 10.5507/bp.2015.010] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
167 Farag E, Maheshwari K, Morgan J, Sakr Esa WA, Doyle DJ. An update of the role of renin angiotensin in cardiovascular homeostasis. Anesth Analg 2015;120:275-92. [PMID: 25602448 DOI: 10.1213/ANE.0000000000000528] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.6] [Reference Citation Analysis]
168 Mehta G, Mookerjee RP, Sharma V, Jalan R. Systemic inflammation is associated with increased intrahepatic resistance and mortality in alcohol-related acute-on-chronic liver failure. Liver Int 2015;35:724-34. [PMID: 24703488 DOI: 10.1111/liv.12559] [Cited by in Crossref: 75] [Cited by in F6Publishing: 69] [Article Influence: 9.4] [Reference Citation Analysis]
169 Deepak A, Mrudul VD, Madhuri C, Rajiv B, Praveen K, Mayank J, Nikhil P, Praful K, Nimish S, Sandeep K, Sonali G, Apurva S, Soham D. Care of patients with liver cirrhosis: How are we doing? J Public Health Epidemiol 2015;7:51-58. [DOI: 10.5897/jphe2014.0695] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
170 Israelsen M, Krag A, Gluud LL. Terlipressin versus other vasoactive drugs for hepatorenal syndrome. Cochrane Database of Systematic Reviews 2015. [DOI: 10.1002/14651858.cd011532] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
171 Egerod Israelsen M, Gluud LL, Krag A. Acute kidney injury and hepatorenal syndrome in cirrhosis. J Gastroenterol Hepatol 2015;30:236-43. [PMID: 25160511 DOI: 10.1111/jgh.12709] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 4.1] [Reference Citation Analysis]
172 Bozanich NK, Kwo PY. Renal insufficiency in the patient with chronic liver disease. Clin Liver Dis 2015;19:45-56. [PMID: 25454296 DOI: 10.1016/j.cld.2014.09.003] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
173 Cárdenas A, Graupera I, Ginès P. Ascites. Cirrhosis: A practical guide to management 2015. [DOI: 10.1002/9781118412640.ch14] [Reference Citation Analysis]
174 Adebayo D, Morabito V, Jalan R. Acute-on-chronic liver failure. Cirrhosis: A practical guide to management 2015. [DOI: 10.1002/9781118412640.ch09] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
175 Piano S, Morando F, Angeli P. Hyponatremia and other electrolyte/ion disorders. Cirrhosis: A practical guide to management 2015. [DOI: 10.1002/9781118412640.ch18] [Reference Citation Analysis]
176 Low G, Alexander GJ, Lomas DJ. Hepatorenal syndrome: aetiology, diagnosis, and treatment. Gastroenterol Res Pract 2015;2015:207012. [PMID: 25649410 DOI: 10.1155/2015/207012] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 3.1] [Reference Citation Analysis]
177 Park SH, Park C, Yoo J, Choi S, Choi J, Shin H, Lee D, Lee S, Kim J, Choi SE, Kwon Y, Shin W. Emergence of Community-Associated Methicillin-Resistant Staphylococcus aureus Strains as a Cause of Healthcare-Associated Bloodstream Infections in Korea. Infect Control Hosp Epidemiol 2009;30:146-55. [DOI: 10.1086/593953] [Cited by in Crossref: 58] [Cited by in F6Publishing: 59] [Article Influence: 7.3] [Reference Citation Analysis]
178 Pham PT, Parke C, Allamezadeh R, Pham PT, Danovitch GM. Renal Failure in Adults. Transplantation of the Liver 2015. [DOI: 10.1016/b978-1-4557-0268-8.00074-9] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
179 Fayad L, Narciso-Schiavon JL, Lazzarotto C, Ronsoni MF, Wildner LM, Bazzo ML, Schiavon Lde L, Dantas-Corrêa EB. The performance of prognostic models as predictors of mortality in patients with acute decompensation of cirrhosis. Ann Hepatol 2015;14:83-92. [PMID: 25536645] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
180 Mai ML, Wadei HM. Pretransplantation Evaluation. Transplantation of the Liver 2015. [DOI: 10.1016/b978-1-4557-0268-8.00032-4] [Reference Citation Analysis]
181 Jahn M, Bienholz A, Kribben A. Akutes Nierenversagen: Pathophysiologie, Prävention, Therapie und Sonderformen. DGIM Innere Medizin 2015. [DOI: 10.1007/978-3-642-54676-1_75-1] [Reference Citation Analysis]
182 Marik PE. Acute and Chronic Liver Disease. Evidence-Based Critical Care 2015. [DOI: 10.1007/978-3-319-11020-2_34] [Reference Citation Analysis]
183 Bernardi M, Ricci CS, Santi L. Hyponatremia in Patients with Cirrhosis of the Liver. J Clin Med. 2014;4:85-101. [PMID: 26237020 DOI: 10.3390/jcm4010085] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
184 Cimen S, Guler S, Ayloo S, Molinari M. Implications of Hyponatremia in Liver Transplantation. J Clin Med 2014;4:66-74. [PMID: 26237018 DOI: 10.3390/jcm4010066] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
185 Ennaifer R, Romdhane H, Hefaiedh R, Nejma HB, Hadj NB. Insuffisance rénale aigüe chez le patient cirrhotique : particularités diagnostiques et thérapeutiques. J Afr Hepato Gastroenterol 2014;8:189-194. [DOI: 10.1007/s12157-014-0552-x] [Reference Citation Analysis]
186 Facciorusso A, Amoruso A, Neve V, Antonino M, Prete VD, Barone M. Role of vaptans in the management of hydroelectrolytic imbalance in liver cirrhosis. World J Hepatol 2014; 6(11): 793-799 [PMID: 25429317 DOI: 10.4254/wjh.v6.i11.793] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
187 Chan AC, Fan ST. Criteria for liver transplantation in ACLF and outcome. Hepatol Int. 2015;9:355-359. [PMID: 25788183 DOI: 10.1007/s12072-014-9585-x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
188 Siddiqui MS, Stravitz RT. Intensive care unit management of patients with liver failure. Clin Liver Dis 2014;18:957-78. [PMID: 25438294 DOI: 10.1016/j.cld.2014.07.012] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
189 DellaVolpe JD, Garavaglia JM, Huang DT. Management of Complications of End-Stage Liver Disease in the Intensive Care Unit. J Intensive Care Med 2016;31:94-103. [PMID: 25223828 DOI: 10.1177/0885066614551144] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
190 Nassar Junior AP, Farias AQ, D' Albuquerque LA, Carrilho FJ, Malbouisson LM. Terlipressin versus norepinephrine in the treatment of hepatorenal syndrome: a systematic review and meta-analysis. PLoS One 2014;9:e107466. [PMID: 25203311 DOI: 10.1371/journal.pone.0107466] [Cited by in Crossref: 94] [Cited by in F6Publishing: 98] [Article Influence: 10.4] [Reference Citation Analysis]
191 Torruellas C, French SW, Medici V. Diagnosis of alcoholic liver disease. World J Gastroenterol 2014; 20(33): 11684-11699 [PMID: 25206273 DOI: 10.3748/wjg.v20.i33.11684] [Cited by in CrossRef: 84] [Cited by in F6Publishing: 93] [Article Influence: 9.3] [Reference Citation Analysis]
192 Arroyo V, García-Martinez R, Salvatella X. Human serum albumin, systemic inflammation, and cirrhosis. J Hepatol 2014;61:396-407. [PMID: 24751830 DOI: 10.1016/j.jhep.2014.04.012] [Cited by in Crossref: 281] [Cited by in F6Publishing: 285] [Article Influence: 31.2] [Reference Citation Analysis]
193 Biolato M, Miele L, Vero V, Racco S, Stasi CD, Iezzi R, Zanché A, Pompili M, Rapaccini GL, Torre GL, Gasbarrini A, Grieco A. Hepatocellular carcinoma treated by conventional transarterial chemoembolization in field-practice: Serum sodium predicts survival. World J Gastroenterol 2014; 20(25): 8158-8165 [PMID: 25009388 DOI: 10.3748/wjg.v20.i25.8158] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
194 Leise MD, Yun BC, Larson JJ, Benson JT, Yang JD, Therneau TM, Rosen CB, Heimbach JK, Biggins SW, Kim WR. Effect of the pretransplant serum sodium concentration on outcomes following liver transplantation. Liver Transpl 2014;20:687-97. [PMID: 24616214 DOI: 10.1002/lt.23860] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 3.6] [Reference Citation Analysis]
195 Vukobrat-Bijedic Z, Husic-Selimovic A, Mehinovic L, Junuzovic D, Bijedic N, Sofic A, Bjelogrlic I, Mehmedovic A. Estimated Glomerular Filtration Rate (eGFR) Values as Predictor of Renal Insufficiency in Advanced Stages of Liver Diseases with Different Etiology. Med Arch 2014;68:159-62. [PMID: 25568524 DOI: 10.5455/medarh.2014.68.159-162] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
196 Ripoll C, Zipprich A, Garcia-tsao G. Prognostic Factors in Compensated and Decompensated Cirrhosis. Curr Hepatology Rep 2014;13:171-9. [DOI: 10.1007/s11901-014-0234-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
197 Nusrat S, Khan MS, Fazili J, Madhoun MF. Cirrhosis and its complications: Evidence based treatment. World J Gastroenterol 2014; 20(18): 5442-5460 [PMID: 24833875 DOI: 10.3748/wjg.v20.i18.5442] [Cited by in CrossRef: 118] [Cited by in F6Publishing: 128] [Article Influence: 13.1] [Reference Citation Analysis]
198 Pugliese R, Fonseca EA, Porta G, Danesi V, Guimaraes T, Porta A, Miura IK, Borges C, Candido H, Benavides M, Feier FH, Godoy A, Cardoso RA, Kondo M, Chapchap P, Neto JS. Ascites and serum sodium are markers of increased waiting list mortality in children with chronic liver failure. Hepatology 2014;59:1964-71. [PMID: 24122953 DOI: 10.1002/hep.26776] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 4.6] [Reference Citation Analysis]
199 Francoz C, Nadim MK, Baron A, Prié D, Antoine C, Belghiti J, Valla D, Moreau R, Durand F. Glomerular filtration rate equations for liver-kidney transplantation in patients with cirrhosis: validation of current recommendations. Hepatology 2014;59:1514-21. [PMID: 24037821 DOI: 10.1002/hep.26704] [Cited by in Crossref: 96] [Cited by in F6Publishing: 71] [Article Influence: 10.7] [Reference Citation Analysis]
200 Leithead JA, Hayes PC, Ferguson JW. Review article: advances in the management of patients with cirrhosis and portal hypertension-related renal dysfunction. Aliment Pharmacol Ther 2014;39:699-711. [PMID: 24528130 DOI: 10.1111/apt.12653] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
201 Abu Zeinah GF, Al-Kindi SG, Hassan AA, Allam A. Hyponatraemia in cancer: association with type of cancer and mortality. Eur J Cancer Care (Engl) 2015;24:224-31. [PMID: 24661476 DOI: 10.1111/ecc.12187] [Cited by in Crossref: 30] [Cited by in F6Publishing: 33] [Article Influence: 3.3] [Reference Citation Analysis]
202 Maddukuri G, Cai CX, Munigala S, Mohammadi F, Zhang Z. Targeting an early and substantial increase in mean arterial pressure is critical in the management of type 1 hepatorenal syndrome: a combined retrospective and pilot study. Dig Dis Sci 2014;59:471-81. [PMID: 24146317 DOI: 10.1007/s10620-013-2899-z] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
203 Bonder A, Botero ML, Cardenas A. Current Therapies for Hepatorenal Syndrome. Curr Hepatology Rep 2014;13:74-80. [DOI: 10.1007/s11901-014-0217-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
204 Zhang X, Huang S, Gao M, Liu J, Jia X, Han Q, Zheng S, Miao Y, Li S, Weng H, Xia X, Du S, Wu W, Gustafsson JÅ, Guan Y. Farnesoid X receptor (FXR) gene deficiency impairs urine concentration in mice. Proc Natl Acad Sci U S A 2014;111:2277-82. [PMID: 24464484 DOI: 10.1073/pnas.1323977111] [Cited by in Crossref: 52] [Cited by in F6Publishing: 56] [Article Influence: 5.8] [Reference Citation Analysis]
205 Seo JH, Kim SU, Park JY, Kim DY, Han KH, Chon CY, Ahn SH. Predictors of refractory ascites development in patients with hepatitis B virus-related cirrhosis hospitalized to control ascitic decompensation. Yonsei Med J 2013;54:145-53. [PMID: 23225811 DOI: 10.3349/ymj.2013.54.1.145] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
206 Fabrizi F, Martin P, Messa P. Recent advances in the management of hepato-renal syndrome (HRS). Acta Clin Belg 2007;62 Suppl 2:393-6. [PMID: 18284007 DOI: 10.1179/acb.2007.088] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
207 Kiser TH. Hepatorenal Syndrome. Int J Clin Med 2014;5:102-10. [PMID: 32284909 DOI: 10.4236/ijcm.2014.53018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
208 Miyoshi T, Kitamura K. 8. Distant Organ Dysfunction Associated with AKI. J Jpn Soc Intern Med 2014;103:1123-1129. [DOI: 10.2169/naika.103.1123] [Reference Citation Analysis]
209 Carey EJ, Rakela J, Vargas HE. Monitoring and Care. Transplantation of the Liver 2014. [DOI: 10.1016/b978-1-4557-0268-8.00036-1] [Reference Citation Analysis]
210 O’riordan A. Hepatorenal Syndrome. Practical Nephrology 2014. [DOI: 10.1007/978-1-4471-5547-8_8] [Reference Citation Analysis]
211 Pillebout E. Hepatorenal syndrome. Nephrol Ther. 2014;10:61-68. [PMID: 24388293 DOI: 10.1016/j.nephro.2013.11.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
212 Licata A, Maida M, Bonaccorso A, Macaluso FS, Cappello M, Craxì A, Almasio PL. Clinical course and prognostic factors of hepatorenal syndrome: A retrospective single-center cohort study. World J Hepatol 2013; 5(12): 685-691 [PMID: 24432185 DOI: 10.4254/wjh.v5.i12.685] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 2.4] [Reference Citation Analysis]
213 Chan MM, Chan MM, Mengshol JA, Fish DN, Chan ED. Octreotide. Chest 2013;144:1937-45. [DOI: 10.1378/chest.13-0382] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
214 Verbalis JG, Goldsmith SR, Greenberg A, Korzelius C, Schrier RW, Sterns RH, Thompson CJ. Diagnosis, evaluation, and treatment of hyponatremia: expert panel recommendations. Am J Med. 2013;126:S1-S42. [PMID: 24074529 DOI: 10.1016/j.amjmed.2013.07.006] [Cited by in Crossref: 582] [Cited by in F6Publishing: 633] [Article Influence: 58.2] [Reference Citation Analysis]
215 Schutz FA, Xie W, Donskov F, Sircar M, McDermott DF, Rini BI, Agarwal N, Pal SK, Srinivas S, Kollmannsberger C, North SA, Wood LA, Vaishampayan U, Tan MH, Mackenzie MJ, Lee JL, Rha SY, Yuasa T, Heng DY, Choueiri TK. The impact of low serum sodium on treatment outcome of targeted therapy in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Cancer Database Consortium. Eur Urol 2014;65:723-30. [PMID: 24184025 DOI: 10.1016/j.eururo.2013.10.013] [Cited by in Crossref: 56] [Cited by in F6Publishing: 56] [Article Influence: 5.6] [Reference Citation Analysis]
216 Verna EC, Wagener G. Renal interactions in liver dysfunction and failure. Curr Opin Crit Care 2013;19:133-41. [PMID: 23422161 DOI: 10.1097/MCC.0b013e32835ebb3a] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
217 Barone C, Koeberle D, Metselaar H, Parisi G, Sansonno D, Spinzi G. Multidisciplinary approach for HCC patients: hepatology for the oncologists. Ann Oncol. 2013;24 Suppl 2:ii15-ii23. [PMID: 23715939 DOI: 10.1093/annonc/mdt053] [Cited by in Crossref: 17] [Cited by in F6Publishing: 23] [Article Influence: 1.7] [Reference Citation Analysis]
218 Mohindra S, Kumar K. Hepatorenal syndrome. Clinical Queries: Nephrology 2013;2:205-211. [DOI: 10.1016/j.cqn.2013.11.002] [Reference Citation Analysis]
219 Ghosh S, Choudhary NS, Sharma AK, Singh B, Kumar P, Agarwal R, Sharma N, Bhalla A, Chawla YK, Singh V. Noradrenaline vs terlipressin in the treatment of type 2 hepatorenal syndrome: a randomized pilot study. Liver Int 2013;33:1187-93. [PMID: 23601499 DOI: 10.1111/liv.12179] [Cited by in Crossref: 63] [Cited by in F6Publishing: 60] [Article Influence: 6.3] [Reference Citation Analysis]
220 Huschak G, Kaisers U, Laudi S. Hepatorenales Syndrom. Anaesthesist 2013;62:571-82. [DOI: 10.1007/s00101-013-2197-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
221 Götzberger M, Singer J, Kaiser C, Gülberg V. Intrarenal resistance index as a prognostic parameter in patients with liver cirrhosis compared with other hepatic scoring systems. Digestion 2012;86:349-54. [PMID: 23207318 DOI: 10.1159/000343459] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
222 Xing T, Zhong L, Chen D, Peng Z. Experience of Combined Liver-Kidney Transplantation for Acute-on-Chronic Liver Failure Patients With Renal Dysfunction. Transplantation Proceedings 2013;45:2307-13. [DOI: 10.1016/j.transproceed.2013.02.127] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 2.0] [Reference Citation Analysis]
223 Kim HJ, Lee HW. Important predictor of mortality in patients with end-stage liver disease. Clin Mol Hepatol. 2013;19:105-115. [PMID: 23837134 DOI: 10.3350/cmh.2013.19.2.105] [Cited by in Crossref: 67] [Cited by in F6Publishing: 74] [Article Influence: 6.7] [Reference Citation Analysis]
224 Allegretti AS, Steele DJ, David-Kasdan JA, Bajwa E, Niles JL, Bhan I. Continuous renal replacement therapy outcomes in acute kidney injury and end-stage renal disease: a cohort study. Crit Care 2013;17:R109. [PMID: 23782899 DOI: 10.1186/cc12780] [Cited by in Crossref: 58] [Cited by in F6Publishing: 58] [Article Influence: 5.8] [Reference Citation Analysis]
225 Bertot LC, Gomez EV, Almeida LA, Soler EA, Perez LB. Model for End-Stage Liver Disease and liver cirrhosis-related complications. Hepatol Int 2013;7:347-55. [PMID: 26201769 DOI: 10.1007/s12072-012-9403-2] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
226 Gülberg V, Gerbes A. Komplikationen der Leberzirrhose. Gastroenterologe 2013;8:241-249. [DOI: 10.1007/s11377-013-0751-9] [Reference Citation Analysis]
227 van Slambrouck CM, Salem F, Meehan SM, Chang A. Bile cast nephropathy is a common pathologic finding for kidney injury associated with severe liver dysfunction. Kidney Int. 2013;84:192-197. [PMID: 23486516 DOI: 10.1038/ki.2013.78] [Cited by in Crossref: 135] [Cited by in F6Publishing: 141] [Article Influence: 13.5] [Reference Citation Analysis]
228 Shah N, Mohamed FE, Jover-Cobos M, Macnaughtan J, Davies N, Moreau R, Paradis V, Moore K, Mookerjee R, Jalan R. Increased renal expression and urinary excretion of TLR4 in acute kidney injury associated with cirrhosis. Liver Int 2013;33:398-409. [PMID: 23402610 DOI: 10.1111/liv.12047] [Cited by in Crossref: 80] [Cited by in F6Publishing: 78] [Article Influence: 8.0] [Reference Citation Analysis]
229 Lau T, Ahmad J. Clinical applications of the Model for End-Stage Liver Disease (MELD) in hepatic medicine. Hepat Med. 2013;5:1-10. [PMID: 24696621 DOI: 10.2147/hmer.s9049] [Cited by in Crossref: 7] [Cited by in F6Publishing: 14] [Article Influence: 0.7] [Reference Citation Analysis]
230 Solà E, Cárdenas A, Ginès P. Hyponatremia in Cirrhosis: Evaluation and Treatment. Hyponatremia 2013. [DOI: 10.1007/978-1-4614-6645-1_8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
231 Judd EK, Mehta S, Tolwani AJ. Specific Etiologies. Clinical Decisions in Nephrology, Hypertension and Kidney Transplantation 2013. [DOI: 10.1007/978-1-4614-4454-1_21] [Reference Citation Analysis]
232 Fukazawa K, Lee HT. Updates on Hepato-Renal Syndrome. J Anesth Clin Res. 2013;4:352. [PMID: 24459604 DOI: 10.4172/2155-6148.1000352] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 0.3] [Reference Citation Analysis]
233 Ginès P, Cárdenas A, Schrier RW. Renal Failure in Cirrhosis. Seldin and Giebisch's The Kidney. Elsevier; 2013. pp. 2633-44. [DOI: 10.1016/b978-0-12-381462-3.00079-3] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
234 Jafri S, Gordon SC. Care of the Cirrhotic Patient. Infectious Disease Clinics of North America 2012;26:979-94. [DOI: 10.1016/j.idc.2012.08.009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
235 Schrier RW, Sharma S, Shchekochikhin D. Hyponatraemia: more than just a marker of disease severity? Nat Rev Nephrol. 2013;9:37-50. [PMID: 23165296 DOI: 10.1038/nrneph.2012.246] [Cited by in Crossref: 52] [Cited by in F6Publishing: 58] [Article Influence: 4.7] [Reference Citation Analysis]
236 Weber ML, Ibrahim HN, Lake JR. Renal dysfunction in liver transplant recipients: evaluation of the critical issues. Liver Transpl 2012;18:1290-301. [PMID: 22847917 DOI: 10.1002/lt.23522] [Cited by in Crossref: 79] [Cited by in F6Publishing: 71] [Article Influence: 7.2] [Reference Citation Analysis]
237 Lata J. Hepatorenal syndrome. World J Gastroenterol 2012; 18(36): 4978-4984 [PMID: 23049205 DOI: 10.3748/wjg.v18.i36.4978] [Cited by in CrossRef: 46] [Cited by in F6Publishing: 49] [Article Influence: 4.2] [Reference Citation Analysis]
238 Al-Busafi SA, McNabb-Baltar J, Farag A, Hilzenrat N. Clinical manifestations of portal hypertension. Int J Hepatol. 2012;2012:203794. [PMID: 23024865 DOI: 10.1155/2012/203794] [Cited by in Crossref: 32] [Cited by in F6Publishing: 67] [Article Influence: 2.9] [Reference Citation Analysis]
239 Davenport A. AKI in a patient with cirrhosis and ascites. Clin J Am Soc Nephrol. 2012;7:2041-2048. [PMID: 22977213 DOI: 10.2215/cjn.03390412] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
240 Gluud LL, Christensen K, Christensen E, Krag A. Terlipressin for hepatorenal syndrome. Cochrane Database Syst Rev. 2012;9:CD005162. [PMID: 22972083 DOI: 10.1002/14651858.cd005162.pub3] [Cited by in Crossref: 43] [Cited by in F6Publishing: 66] [Article Influence: 3.9] [Reference Citation Analysis]
241 Makhlouf NA, Morsy KH. Renal failure after upper-gastrointestinal bleeding among cirrhotic patients in Upper Egypt. Arab J Gastroenterol 2012;13:139-44. [PMID: 23122456 DOI: 10.1016/j.ajg.2012.08.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
242 Verna EC, Brown RS, Farrand E, Pichardo EM, Forster CS, Sola-Del Valle DA, Adkins SH, Sise ME, Oliver JA, Radhakrishnan J, Barasch JM, Nickolas TL. Urinary neutrophil gelatinase-associated lipocalin predicts mortality and identifies acute kidney injury in cirrhosis. Dig Dis Sci 2012;57:2362-70. [PMID: 22562534 DOI: 10.1007/s10620-012-2180-x] [Cited by in Crossref: 110] [Cited by in F6Publishing: 104] [Article Influence: 10.0] [Reference Citation Analysis]
243 Hartleb M, Gutkowski K. Kidneys in chronic liver diseases. World J Gastroenterol 2012; 18(24): 3035-3049 [PMID: 22791939 DOI: 10.3748/wjg.v18.i24.3035] [Cited by in CrossRef: 52] [Cited by in F6Publishing: 54] [Article Influence: 4.7] [Reference Citation Analysis]
244 Grace JA, Herath CB, Mak KY, Burrell LM, Angus PW. Update on new aspects of the renin-angiotensin system in liver disease: clinical implications and new therapeutic options. Clin Sci (Lond). 2012;123:225-239. [PMID: 22548407 DOI: 10.1042/cs20120030] [Cited by in Crossref: 67] [Cited by in F6Publishing: 73] [Article Influence: 6.1] [Reference Citation Analysis]
245 Singh V, Ghosh S, Singh B, Kumar P, Sharma N, Bhalla A, Sharma AK, Choudhary NS, Chawla Y, Nain CK. Noradrenaline vs. terlipressin in the treatment of hepatorenal syndrome: a randomized study. J Hepatol 2012;56:1293-8. [PMID: 22322237 DOI: 10.1016/j.jhep.2012.01.012] [Cited by in Crossref: 168] [Cited by in F6Publishing: 173] [Article Influence: 15.3] [Reference Citation Analysis]
246 Tan H, Schiano TD. Effects of Liver Disease on Drug Metabolism in Humans. Encyclopedia of Drug Metabolism and Interactions. Hoboken: John Wiley & Sons, Inc.; 2011. [DOI: 10.1002/9780470921920.edm125] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
247 Gordon FD. Ascites. Clin Liver Dis 2012;16:285-99. [PMID: 22541699 DOI: 10.1016/j.cld.2012.03.004] [Cited by in Crossref: 26] [Cited by in F6Publishing: 29] [Article Influence: 2.4] [Reference Citation Analysis]
248 Coilly A, Samuel D. Selection and Evaluation of the Recipient (Including Retransplantation). Medical Care of the Liver Transplant Patient 2012. [DOI: 10.1002/9781444398441.ch1] [Reference Citation Analysis]
249 Fagundes C, Ginès P. Hepatorenal syndrome: a severe, but treatable, cause of kidney failure in cirrhosis. Am J Kidney Dis. 2012;59:874-885. [PMID: 22480795 DOI: 10.1053/j.ajkd.2011.12.032] [Cited by in Crossref: 45] [Cited by in F6Publishing: 48] [Article Influence: 4.1] [Reference Citation Analysis]
250 Fede G, D'Amico G, Arvaniti V, Tsochatzis E, Germani G, Georgiadis D, Morabito A, Burroughs AK. Renal failure and cirrhosis: a systematic review of mortality and prognosis. J Hepatol 2012;56:810-8. [PMID: 22173162 DOI: 10.1016/j.jhep.2011.10.016] [Cited by in Crossref: 185] [Cited by in F6Publishing: 186] [Article Influence: 16.8] [Reference Citation Analysis]
251 Schrier RW. Use of diuretics in heart failure and cirrhosis. Semin Nephrol 2011;31:503-12. [PMID: 22099507 DOI: 10.1016/j.semnephrol.2011.09.005] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.9] [Reference Citation Analysis]
252 Narahara Y, Kanazawa H, Sakamoto C, Maruyama H, Yokosuka O, Mochida S, Uemura M, Fukui H, Sumino Y, Matsuzaki Y, Masaki N, Kokubu S, Okita K. The efficacy and safety of terlipressin and albumin in patients with type 1 hepatorenal syndrome: a multicenter, open-label, explorative study. J Gastroenterol 2012;47:313-20. [PMID: 22038555 DOI: 10.1007/s00535-011-0485-8] [Cited by in Crossref: 13] [Cited by in F6Publishing: 18] [Article Influence: 1.2] [Reference Citation Analysis]
253 Nadim MK, Kellum JA, Davenport A, Wong F, Davis C, Pannu N, Tolwani A, Bellomo R, Genyk YS;  ADQI Workgroup. Hepatorenal syndrome: the 8th International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care. 2012;16:R23. [PMID: 22322077 DOI: 10.1186/cc11188] [Cited by in Crossref: 112] [Cited by in F6Publishing: 121] [Article Influence: 10.2] [Reference Citation Analysis]
254 Olivera-Martinez M, Sayles H, Vivekanandan R, D' Souza S, Florescu MC. Hepatorenal syndrome: are we missing some prognostic factors? Dig Dis Sci 2012;57:210-4. [PMID: 21850494 DOI: 10.1007/s10620-011-1861-1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
255 Garcia-tsao G. Ascites. Zakim and Boyer's Hepatology. Elsevier; 2012. pp. 283-95. [DOI: 10.1016/b978-1-4377-0881-3.00018-8] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
256 Diaz G. Combined Solid Organ Transplantation Involving the Liver. Liver Anesthesiology and Critical Care Medicine 2012. [DOI: 10.1007/978-1-4614-5167-9_17] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
257 Levesque E, Hoti E, Azoulay D, Ichaï P, Habouchi H, Castaing D, Samuel D, Saliba F. Prospective evaluation of the prognostic scores for cirrhotic patients admitted to an intensive care unit. J Hepatol 2012;56:95-102. [PMID: 21835136 DOI: 10.1016/j.jhep.2011.06.024] [Cited by in Crossref: 129] [Cited by in F6Publishing: 125] [Article Influence: 11.7] [Reference Citation Analysis]
258 Susla GM, Lertora JJ. Effect of Liver Disease on Pharmacokinetics. Principles of Clinical Pharmacology 2012. [DOI: 10.1016/b978-0-12-385471-1.00007-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
259 Ginès P, Fernández J, Durand F, Saliba F. Management of critically-ill cirrhotic patients. J Hepatol 2012;56 Suppl 1:S13-24. [PMID: 22300462 DOI: 10.1016/S0168-8278(12)60003-8] [Cited by in Crossref: 96] [Cited by in F6Publishing: 90] [Article Influence: 8.7] [Reference Citation Analysis]
260 Fanali G, di Masi A, Trezza V, Marino M, Fasano M, Ascenzi P. Human serum albumin: from bench to bedside. Mol Aspects Med 2012;33:209-90. [PMID: 22230555 DOI: 10.1016/j.mam.2011.12.002] [Cited by in Crossref: 983] [Cited by in F6Publishing: 1030] [Article Influence: 81.9] [Reference Citation Analysis]
261 Laleman W, Verbeke L, Meersseman P, Wauters J, van Pelt J, Cassiman D, Wilmer A, Verslype C, Nevens F. Acute-on-chronic liver failure: current concepts on definition, pathogenesis, clinical manifestations and potential therapeutic interventions. Expert Rev Gastroenterol Hepatol. 2011;5:523-537; quiz 537. [PMID: 21780899 DOI: 10.1586/egh.11.47] [Cited by in Crossref: 66] [Cited by in F6Publishing: 72] [Article Influence: 5.5] [Reference Citation Analysis]
262 Patterson JH. Hyponatremia's Impact on Patients and Health Systems. Hosp Pharm 2011;46:3-10. [DOI: 10.1310/hpj4612-s3] [Reference Citation Analysis]
263 Tahir F, Riaz H, Rehman A, Munir MB. Potential role of TNF alpha blockers in delaying the progression of hepato-renal syndrome. Med Hypotheses. 2012;78:225-226. [PMID: 22094211 DOI: 10.1016/j.mehy.2011.10.030] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
264 Kim DJ, Kang HS, Choi HS, Cho HJ, Kim ES, Keum B, An H, Kim JH, Seo YS, Kim YS. Serum cystatin C level is a useful marker for the evaluation of renal function in patients with cirrhotic ascites and normal serum creatinine levels. Korean J Hepatol. 2011;17:130-138. [PMID: 21757984 DOI: 10.3350/kjhep.2011.17.2.130] [Cited by in Crossref: 16] [Cited by in F6Publishing: 22] [Article Influence: 1.3] [Reference Citation Analysis]
265 Gundling F, Schmidt T, Schepp W. Common complications of cirrhosis: do we follow too often the 'Casablanca strategy'? Liver Int 2011;31:1598-600. [PMID: 21745306 DOI: 10.1111/j.1478-3231.2011.02565.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
266 Boyer TD, Sanyal AJ, Garcia-Tsao G, Regenstein F, Rossaro L, Appenrodt B, Gülberg V, Sigal S, Bexon AS, Teuber P; Terlipressin Study Group. Impact of liver transplantation on the survival of patients treated for hepatorenal syndrome type 1. Liver Transpl 2011;17:1328-32. [PMID: 21837734 DOI: 10.1002/lt.22395] [Cited by in Crossref: 79] [Cited by in F6Publishing: 79] [Article Influence: 6.6] [Reference Citation Analysis]
267 Tan HH, Martin P. Care of the liver transplant candidate. Clin Liver Dis 2011;15:779-806. [PMID: 22032529 DOI: 10.1016/j.cld.2011.08.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
268 Madan K, Mehta A. Management of renal failure and ascites in patients with cirrhosis. Int J Hepatol 2011;2011:790232. [PMID: 21994871 DOI: 10.4061/2011/790232] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
269 Memon I, Klein CL. Impact of hepatorenal syndrome and liver transplantation. Curr Opin Organ Transplant 2011;16:301-5. [PMID: 21505341 DOI: 10.1097/MOT.0b013e328346576c] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
270 Srivastava B, Alexander GJ. Renal failure in chronic liver disease and the hepatorenal syndrome. British Journal of Hospital Medicine 2011;72:497-503. [DOI: 10.12968/hmed.2011.72.9.497] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
271 Patel PA, Lowe E, Baig W, Sandoe J. Hepatorenal syndrome precipitated by infective endocarditis. British Journal of Hospital Medicine 2011;72:532-3. [DOI: 10.12968/hmed.2011.72.9.532] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
272 Wadei HM, Gonwa TA. Hepatorenal syndrome in the intensive care unit. J Intensive Care Med. 2013;28:79-92. [PMID: 21859679 DOI: 10.1177/0885066611408692] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 0.6] [Reference Citation Analysis]
273 Dancygier H. Aszites. DoctorConsult - The Journal Wissen für Klinik und Praxis 2011;2:e87-e96. [DOI: 10.1016/j.dcjwkp.2011.07.006] [Reference Citation Analysis]
274 Boyer TD, Sanyal AJ, Garcia-Tsao G, Blei A, Carl D, Bexon AS, Teuber P; Terlipressin Study Group. Predictors of response to terlipressin plus albumin in hepatorenal syndrome (HRS) type 1: relationship of serum creatinine to hemodynamics. J Hepatol 2011;55:315-21. [PMID: 21167235 DOI: 10.1016/j.jhep.2010.11.020] [Cited by in Crossref: 161] [Cited by in F6Publishing: 164] [Article Influence: 13.4] [Reference Citation Analysis]
275 Sarin SK, Sharma P. Terlipressin: an asset for hepatologists! Hepatology 2011;54:724-8. [PMID: 21735463 DOI: 10.1002/hep.24519] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
276 Rice JP, Skagen C, Said A. Liver transplant outcomes for patients with hepatorenal syndrome treated with pretransplant vasoconstrictors and albumin. Transplantation. 2011;91:1141-1147. [PMID: 21544034 DOI: 10.1097/tp.0b013e31821690bf] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 2.3] [Reference Citation Analysis]
277 Prakash J, Mahapatra AK, Ghosh B, Arora P, Jain AK. Clinical spectrum of renal disorders in patients with cirrhosis of liver. Ren Fail 2011;33:40-6. [PMID: 21219204 DOI: 10.3109/0886022X.2010.541582] [Cited by in Crossref: 17] [Cited by in F6Publishing: 23] [Article Influence: 1.4] [Reference Citation Analysis]
278 Bernardi M, Gitto S, Biselli M. The MELD score in patients awaiting liver transplant: strengths and weaknesses. J Hepatol 2011;54:1297-306. [PMID: 21145851 DOI: 10.1016/j.jhep.2010.11.008] [Cited by in Crossref: 108] [Cited by in F6Publishing: 107] [Article Influence: 9.0] [Reference Citation Analysis]
279 Leise MD, Kim WR, Kremers WK, Larson JJ, Benson JT, Therneau TM. A revised model for end-stage liver disease optimizes prediction of mortality among patients awaiting liver transplantation. Gastroenterology 2011;140:1952-60. [PMID: 21334338 DOI: 10.1053/j.gastro.2011.02.017] [Cited by in Crossref: 103] [Cited by in F6Publishing: 108] [Article Influence: 8.6] [Reference Citation Analysis]
280 Arora R, Kathuria S, Jalandhara N. Acute renal dysfunction in patients with alcoholic hepatitis. World J Hepatol 2011; 3(5): 121-124 [PMID: 21731905 DOI: 10.4254/wjh.v3.i5.121] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
281 Garcia-tsao G. Ascites. Sherlock's Diseases of the Liver and Biliary System 2011. [DOI: 10.1002/9781444341294.ch10] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
282 Schrier RW. The Science Behind Hyponatremia and Its Clinical Manifestations. Pharmacotherapy 2011;31:9S-17S. [DOI: 10.1592/phco.31.5.9s] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
283 Cerdá J, Tolwani A, Gibney N, Tiranathanagul K. Renal Replacement Therapy in Special Settings: Extracorporeal Support Devices in Liver Failure: EXTRACORPOREAL DEVICES IN LIVER FAILURE. Seminars in Dialysis 2011;24:197-202. [DOI: 10.1111/j.1525-139x.2011.00827.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
284 Al Sibae MR, Cappell MS. Accuracy of MELD scores in predicting mortality in decompensated cirrhosis from variceal bleeding, hepatorenal syndrome, alcoholic hepatitis, or acute liver failure as well as mortality after non-transplant surgery or TIPS. Dig Dis Sci 2011;56:977-87. [PMID: 20844956 DOI: 10.1007/s10620-010-1390-3] [Cited by in Crossref: 52] [Cited by in F6Publishing: 52] [Article Influence: 4.3] [Reference Citation Analysis]
285 Park I, Moon E, Hwang JA, Yu S, Kim BW, Wang HJ, Shin GT, Kim H. Does hepatorenal syndrome affect the result of liver transplantation? Clinical observations. Transplant Proc. 2010;42:2563-2566. [PMID: 20832544 DOI: 10.1016/j.transproceed.2010.04.049] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
286 Somsouk M, Kornfield R, Vittinghoff E, Inadomi JM, Biggins SW. Moderate ascites identifies patients with low model for end-stage liver disease scores awaiting liver transplantation who have a high mortality risk. Liver Transpl 2011;17:129-36. [PMID: 21280185 DOI: 10.1002/lt.22218] [Cited by in Crossref: 62] [Cited by in F6Publishing: 58] [Article Influence: 5.2] [Reference Citation Analysis]
287 Leise MD, Kim WR, Kamath PS. Issues in Transplantation of Patients with Chronic Liver Failure. Chronic Liver Failure 2011. [DOI: 10.1007/978-1-60761-866-9_26] [Reference Citation Analysis]
288 Mazhar SM, Hanna R, Peterson MR, Sirlin CB. Cirrhosis. Abdominal Imaging 2011. [DOI: 10.1016/b978-1-4160-5449-8.00066-4] [Reference Citation Analysis]
289 Coilly A, Samuel D. Cirrhose et transplantation: quand faut-il y penser? Post’U FMC-HGE 2011. [DOI: 10.1007/978-2-8178-0237-4_34] [Reference Citation Analysis]
290 Slack A, Wendon J. Chronic Liver Disease in the Intensive Care. Chronic Liver Failure 2011. [DOI: 10.1007/978-1-60761-866-9_27] [Reference Citation Analysis]
291 Dhillon A. Hepatorenal Syndrome. Textbook of Critical Care 2011. [DOI: 10.1016/b978-1-4377-1367-1.00099-9] [Reference Citation Analysis]
292 Fleming JN, Abou Abbass A. Hepatorenal syndrome: a comprehensive overview for the critical care nurse. Crit Care Nurs Clin North Am 2010;22:351-68. [PMID: 20691386 DOI: 10.1016/j.ccell.2010.03.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
293 Kalambokis GN, Pappas K, Baltayiannis G, Katsanou A, Tsianos EV. Effects of terlipressin on water excretion after oral water load test in nonazotemic cirrhotic patients with ascites without hyponatremia. Scand J Gastroenterol 2010;45:1509-15. [PMID: 20695722 DOI: 10.3109/00365521.2010.510576] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
294 Kim YS. [Ascites, hepatorenal syndrome and spontaneous bacterial peritonitis in patients with portal hypertension]. Korean J Gastroenterol 2010;56:168-85. [PMID: 20847607 DOI: 10.4166/kjg.2010.56.3.168] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
295 Moini M, Hoseini-asl MK, Taghavi SA, Sagheb MM, Nikeghbalian S, Salahi H, Bahador A, Motazedian M, Jafari P, Malek-hosseini SA. Hyponatremia a valuable predictor of early mortality in patients with cirrhosis listed for liver transplantation: Hyponatremia and liver list mortality. Clinical Transplantation 2011;25:638-45. [DOI: 10.1111/j.1399-0012.2010.01350.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 1.8] [Reference Citation Analysis]
296 Canbay A, Witzke O, Gerken G. Hepatorenales Syndrom. Intensivmed 2010;47:565-570. [DOI: 10.1007/s00390-010-0192-3] [Reference Citation Analysis]
297 Bagshaw SM, Bellomo R, Devarajan P, Johnson C, Karvellas CJ, Kutsiogiannis DJ, Mehta R, Pannu N, Romanovsky A, Sheinfeld G, Taylor S, Zappitelli M, Gibney RTN. Review article: Acute kidney injury in critical illness. Can J Anesth/J Can Anesth 2010;57:985-98. [DOI: 10.1007/s12630-010-9375-4] [Cited by in Crossref: 34] [Cited by in F6Publishing: 36] [Article Influence: 2.6] [Reference Citation Analysis]
298 Francoz C, Prié D, Abdelrazek W, Moreau R, Mandot A, Belghiti J, Valla D, Durand F. Inaccuracies of creatinine and creatinine-based equations in candidates for liver transplantation with low creatinine: impact on the model for end-stage liver disease score. Liver Transpl 2010;16:1169-77. [PMID: 20879015 DOI: 10.1002/lt.22128] [Cited by in Crossref: 137] [Cited by in F6Publishing: 94] [Article Influence: 10.5] [Reference Citation Analysis]
299 Barahona-Garrido J, Hernández-Calleros J, Téllez-Avila FI, Chávez-Tapia NC, Remes-Troche JM, Torre A. Bacterial meningitis in cirrhotic patients: case series and description of the prognostic role of acute renal failure. J Clin Gastroenterol 2010;44:e218-23. [PMID: 20453662 DOI: 10.1097/MCG.0b013e3181d88d53] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
300 Rozov-ung I, Panesar M. The use of terlipressin in hepatorenal syndrome. Dial Transplant 2010;39:420-426. [DOI: 10.1002/dat.20492] [Reference Citation Analysis]
301 Ginès P, Cárdenas A, Arroyo V, Rodés J. Ascites, Hepatorenal Syndrome and Spontaneous Bacterial Peritonitis. Evidence‐Based Gastroenterology and Hepatology 2010. [DOI: 10.1002/9781444314403.ch38] [Reference Citation Analysis]
302 European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol 2010;53:397-417. [PMID: 20633946 DOI: 10.1016/j.jhep.2010.05.004] [Cited by in Crossref: 1110] [Cited by in F6Publishing: 1165] [Article Influence: 85.4] [Reference Citation Analysis]
303 Guevara M, Baccaro ME, Ríos J, Martín-Llahí M, Uriz J, Ruiz del Arbol L, Planas R, Monescillo A, Guarner C, Crespo J, Bañares R, Arroyo V, Ginès P. Risk factors for hepatic encephalopathy in patients with cirrhosis and refractory ascites: relevance of serum sodium concentration. Liver Int 2010;30:1137-42. [PMID: 20602681 DOI: 10.1111/j.1478-3231.2010.02293.x] [Cited by in Crossref: 67] [Cited by in F6Publishing: 67] [Article Influence: 5.2] [Reference Citation Analysis]
304 Kumar S, Balki M, Williamson C, Castillo E, Money DM. Disorders of the Liver, Biliary System and Exocrine Pancreas in Pregnancy. de Swiet's Medical Disorders in Obstetric Practice 2010. [DOI: 10.1002/9781444323016.ch9] [Reference Citation Analysis]
305 Javier Brahm B, Rodrigo Quera P. Síndrome hepatorenal: patogénesis y tratamiento. Revista Médica Clínica Las Condes 2010;21:613-622. [DOI: 10.1016/s0716-8640(10)70577-0] [Reference Citation Analysis]
306 Angeli P, Morando F. Optimal management of hepatorenal syndrome in patients with cirrhosis. Hepat Med 2010;2:87-98. [PMID: 24367209 DOI: 10.2147/hmer.s6918] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
307 Gonzalez SA, Trotter JF. Renal function and MELD: being direct is better. J Hepatol 2010;52:622-3. [PMID: 20347171 DOI: 10.1016/j.jhep.2010.01.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
308 Fukuhara T, Ikegami T, Morita K, Umeda K, Ueda S, Nagata S, Sugimachi K, Gion T, Yoshizumi T, Soejima Y, Taketomi A, Maehara Y. Impact of preoperative serum sodium concentration in living donor liver transplantation. J Gastroenterol Hepatol 2010;25:978-84. [PMID: 20546453 DOI: 10.1111/j.1440-1746.2009.06162.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
309 Lim YS, Larson TS, Benson JT, Kamath PS, Kremers WK, Therneau TM, Kim WR. Serum sodium, renal function, and survival of patients with end-stage liver disease. J Hepatol 2010;52:523-8. [PMID: 20185195 DOI: 10.1016/j.jhep.2010.01.009] [Cited by in Crossref: 51] [Cited by in F6Publishing: 53] [Article Influence: 3.9] [Reference Citation Analysis]
310 Triantos CK, Samonakis D, Thalheimer U, Cholongitas E, Senzolo M, Marelli L, Leandro G, Patch D, Burroughs AK. Terlipressin therapy for renal failure in cirrhosis. Eur J Gastroenterol Hepatol 2010;22:481-6. [PMID: 19952764 DOI: 10.1097/MEG.0b013e3283345524] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 1.4] [Reference Citation Analysis]
311 Dobre M, Demirjian S, Sehgal AR, Navaneethan SD. Terlipressin in hepatorenal syndrome: a systematic review and meta-analysis. Int Urol Nephrol 2011;43:175-84. [PMID: 20306131 DOI: 10.1007/s11255-010-9725-8] [Cited by in Crossref: 38] [Cited by in F6Publishing: 45] [Article Influence: 2.9] [Reference Citation Analysis]
312 Jenq CC, Tsai MH, Tian YC, Chang MY, Lin CY, Lien JM, Chen YC, Fang JT, Chen PC, Yang CW. Serum sodium predicts prognosis in critically ill cirrhotic patients. J Clin Gastroenterol 2010;44:220-6. [PMID: 19636261 DOI: 10.1097/MCG.0b013e3181aabbcd] [Cited by in Crossref: 55] [Cited by in F6Publishing: 55] [Article Influence: 4.2] [Reference Citation Analysis]
313 Hsu CY, Lin HC, Huang YH, Su CW, Lee FY, Huo TI, Lee PC, Lee JY, Lee SD. Comparison of the model for end-stage liver disease (MELD), MELD-Na and MELDNa for outcome prediction in patients with acute decompensated hepatitis. Dig Liver Dis 2010;42:137-42. [PMID: 19595648 DOI: 10.1016/j.dld.2009.06.004] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 2.5] [Reference Citation Analysis]
314 Gluud LL, Christensen K, Christensen E, Krag A. Systematic review of randomized trials on vasoconstrictor drugs for hepatorenal syndrome. Hepatology 2010;51:576-84. [PMID: 19885875 DOI: 10.1002/hep.23286] [Cited by in Crossref: 206] [Cited by in F6Publishing: 189] [Article Influence: 15.8] [Reference Citation Analysis]
315 Dancygier H, Rogart JN. Approach to the Patient with Ascites. Clinical Hepatology 2010. [DOI: 10.1007/978-3-540-93842-2_54] [Reference Citation Analysis]
316 Hasper D, Berg T. Hepatorenal Syndrome. Management of Acute Kidney Problems 2010. [DOI: 10.1007/978-3-540-69441-0_31] [Reference Citation Analysis]
317 Dancygier H. Complications of Liver Cirrhosis. Clinical Hepatology 2010. [DOI: 10.1007/978-3-642-04519-6_26] [Reference Citation Analysis]
318 Macdonald AA, Ziegler J, Sinclair L. Nutritional Status in Liver Transplant Recipients. Topics in Clinical Nutrition 2010;25:20-6. [DOI: 10.1097/tin.0b013e3181d108ed] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
319 Cheng IK, Li FF. Hepatorenal Syndrome. Comprehensive Clinical Nephrology 2010. [DOI: 10.1016/b978-0-323-05876-6.00072-1] [Reference Citation Analysis]
320 Müller-marbach A, Häussinger D, Rump L, Vonend O. Das hepatorenale Syndrom. Nephrologe 2010;5:29-42. [DOI: 10.1007/s11560-009-0339-z] [Reference Citation Analysis]
321 Moreau R, Francoz C, Lebrec D, Durand F. Syndrome hépatorénal. Réanimation hépatosplanchnique 2010. [DOI: 10.1016/b978-2-8101-0186-3.50010-2] [Reference Citation Analysis]
322 Carithers RL, Mcclain CJ. Alcoholic Liver Disease. Sleisenger and Fordtran's Gastrointestinal and Liver Disease 2010. [DOI: 10.1016/b978-1-4160-6189-2.00084-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
323 Davenport A. Extracorporeal support for patients with hepatic failure. Hemodial Int. 2003;7:256-263. [PMID: 19379373 DOI: 10.1046/j.1492-7535.2003.00046.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
324 Kiser TH, Maclaren R, Fish DN. Treatment of hepatorenal syndrome. Pharmacotherapy. 2009;29:1196-1211. [PMID: 19792993 DOI: 10.1592/phco.29.10.1196] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 1.4] [Reference Citation Analysis]
325 Appenrodt B, Zielinski J, Brensing KA, Heller J, Sauerbruch T, Schepke M. Degree of hepatic dysfunction and improvement of renal function predict survival in patients with HRS type I: a retrospective analysis. Eur J Gastroenterol Hepatol 2009;21:1428-32. [PMID: 19794309 DOI: 10.1097/MEG.0b013e32832ec16a] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 0.7] [Reference Citation Analysis]
326 Seo YS, Jung ES, An H, Kim JH, Jung YK, Kim JH, Yim HJ, Yeon JE, Byun KS, Kim CD, Ryu HS, Um SH. Serum cystatin C level is a good prognostic marker in patients with cirrhotic ascites and normal serum creatinine levels. Liver Int 2009;29:1521-7. [PMID: 19725889 DOI: 10.1111/j.1478-3231.2009.02105.x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 2.1] [Reference Citation Analysis]
327 Charlton MR, Wall WJ, Ojo AO, Ginès P, Textor S, Shihab FS, Marotta P, Cantarovich M, Eason JD, Wiesner RH, Ramsay MA, Garcia-Valdecasas JC, Neuberger JM, Feng S, Davis CL, Gonwa TA; International Liver Transplantation Society Expert Panel. Report of the first international liver transplantation society expert panel consensus conference on renal insufficiency in liver transplantation. Liver Transpl 2009;15:S1-34. [PMID: 19877213 DOI: 10.1002/lt.21877] [Cited by in Crossref: 114] [Cited by in F6Publishing: 101] [Article Influence: 8.1] [Reference Citation Analysis]
328 Huang HC, Lee FY, Huo TI. Major adverse events, pretransplant assessment and outcome prediction. J Gastroenterol Hepatol 2009;24:1716-24. [PMID: 20136958 DOI: 10.1111/j.1440-1746.2009.06025.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
329 Rochling FA, Zetterman RK. Management of Ascites: . Drugs 2009;69:1739-60. [DOI: 10.2165/11316390-000000000-00000] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
330 Jacqmin S, Ghiglione S, Ozier Y. Le syndrome hépatorénal. Le Praticien en Anesthésie Réanimation 2009;13:262-272. [DOI: 10.1016/j.pratan.2009.07.004] [Reference Citation Analysis]
331 Kalil JR, Cerqueira LA, Barbosa DS, Motta MP, Nery MDS, Bittencourt PL. Poor outcomes with treatment of hepatorenal syndrome type 1 with splancnic vasoconstrictors and albumin: report of seven cases and review of the literature. Arq Gastroenterol 2009;46:214-8. [DOI: 10.1590/s0004-28032009000300014] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
332 Dawwas MF, Lewsey JD, Watson CJ, Gimson AE. The Impact of Serum Potassium Concentration on Mortality After Liver Transplantation: A Cohort Multicenter Study. Transplantation 2009;88:402-10. [DOI: 10.1097/tp.0b013e3181aed8e4] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 1.6] [Reference Citation Analysis]
333 Skagen C, Einstein M, Lucey MR, Said A. Combination treatment with octreotide, midodrine, and albumin improves survival in patients with type 1 and type 2 hepatorenal syndrome. J Clin Gastroenterol 2009;43:680-5. [PMID: 19238094 DOI: 10.1097/MCG.0b013e318188947c] [Cited by in Crossref: 84] [Cited by in F6Publishing: 81] [Article Influence: 6.0] [Reference Citation Analysis]
334 Colmenero J, Castro-Narro G, Navasa M. [The value of MELD in the allocation of priority for liver transplantation candidates]. Gastroenterol Hepatol 2010;33:330-6. [PMID: 19631411 DOI: 10.1016/j.gastrohep.2009.04.007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
335 Mackelaite L, Alsauskas ZC, Ranganna K. Renal failure in patients with cirrhosis. Med Clin North Am 2009;93:855-69, viii. [PMID: 19577118 DOI: 10.1016/j.mcna.2009.03.003] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 1.8] [Reference Citation Analysis]
336 Xu X, Ling Q, Zhang M, Gao F, He Z, You J, Zheng S. Outcome of patients with hepatorenal syndrome type 1 after liver transplantation: Hangzhou experience. Transplantation. 2009;87:1514-1519. [PMID: 19461488 DOI: 10.1097/tp.0b013e3181a4430b] [Cited by in Crossref: 28] [Cited by in F6Publishing: 31] [Article Influence: 2.0] [Reference Citation Analysis]
337 Bansal S, Lindenfeld J, Schrier RW. Sodium Retention in Heart Failure and Cirrhosis: Potential Role of Natriuretic Doses of Mineralocorticoid Antagonist? Circ: Heart Failure 2009;2:370-6. [DOI: 10.1161/circheartfailure.108.821199] [Cited by in Crossref: 80] [Cited by in F6Publishing: 85] [Article Influence: 5.7] [Reference Citation Analysis]
338 Garcia-Tsao G, Lim JK; Members of Veterans Affairs Hepatitis C Resource Center Program. Management and treatment of patients with cirrhosis and portal hypertension: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program. Am J Gastroenterol 2009;104:1802-29. [PMID: 19455106 DOI: 10.1038/ajg.2009.191] [Cited by in Crossref: 177] [Cited by in F6Publishing: 179] [Article Influence: 12.6] [Reference Citation Analysis]
339 Minemura M, Tajiri K, Shimizu Y. Systemic abnormalities in liver disease. World J Gastroenterol 2009;15:2960-74. [PMID: 19554648 DOI: 10.3748/wjg.15.2960] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 23] [Article Influence: 1.7] [Reference Citation Analysis]
340 Kayali Z, Herring J, Baron P, Franco E, Ojogho O, Smith J, Watkins G, Smith D, Lamin V, Hoang T, Sharma R, Mathahs M, Sowers L, Brown KE, Schmidt WN. Increased plasma nitric oxide, L-arginine, and arginase-1 in cirrhotic patients with progressive renal dysfunction. J Gastroenterol Hepatol 2009;24:1030-7. [PMID: 19226382 DOI: 10.1111/j.1440-1746.2008.05757.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
341 Poordad FF, Sigal SH, Brown RS. Pathophysiologic basis for the medical management of portal hypertension. Expert Opin Pharmacother. 2009;10:453-467. [PMID: 19191681 DOI: 10.1517/14656560802707853] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
342 Kim JH, Kim JH, Choi JH, Kim CH, Jung YK, Yim HJ, Yeon JE, Park JJ, Kim JS, Bak YT, Byun KS. Value of the model for end-stage liver disease for predicting survival in hepatocellular carcinoma patients treated with transarterial chemoembolization. Scand J Gastroenterol 2009;44:346-57. [PMID: 18991165 DOI: 10.1080/00365520802530838] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
343 Yun BC, Kim WR, Benson JT, Biggins SW, Therneau TM, Kremers WK, Rosen CB, Klintmalm GB. Impact of pretransplant hyponatremia on outcome following liver transplantation. Hepatology 2009;49:1610-5. [PMID: 19402063 DOI: 10.1002/hep.22846] [Cited by in Crossref: 103] [Cited by in F6Publishing: 86] [Article Influence: 7.4] [Reference Citation Analysis]
344 Alessandria C, Debernardi-Venon W, Carello M, Ceretto S, Rizzetto M, Marzano A. Midodrine in the prevention of hepatorenal syndrome type 2 recurrence: a case-control study. Dig Liver Dis 2009;41:298-302. [PMID: 19158001 DOI: 10.1016/j.dld.2008.09.014] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
345 Karwa R, Woodis CB. Midodrine and Octreotide in Treatment of Cirrhosis-Related Hemodynamic Complications. Ann Pharmacother 2009;43:692-9. [DOI: 10.1345/aph.1l373] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 1.4] [Reference Citation Analysis]
346 Lodhia N, Kader M, Mayes T, Mantry P, Maliakkal B. Risk of contrast-induced nephropathy in hospitalized patients with cirrhosis. World J Gastroenterol 2009; 15(12): 1459-1464 [PMID: 19322918 DOI: 10.3748/wjg.15.1459] [Cited by in CrossRef: 28] [Cited by in F6Publishing: 28] [Article Influence: 2.0] [Reference Citation Analysis]
347 Hepatorenal syndrome. Hepatology Textbook and Atlas. [DOI: 10.1007/978-3-540-76839-5_17] [Reference Citation Analysis]
348 Hackworth WA, Sanyal AJ. Review: Vasoconstrictors for the treatment of portal hypertension. Therap Adv Gastroenterol 2009;2:119-31. [DOI: 10.1177/1756283x09102330] [Reference Citation Analysis]
349 Argo CK, Balogun RA. Blood products, volume control, and renal support in the coagulopathy of liver disease. Clin Liver Dis 2009;13:73-85. [PMID: 19150312 DOI: 10.1016/j.cld.2008.09.007] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
350 Arroyo V, Fernández J. Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome. Critical Care Nephrology 2009. [DOI: 10.1016/b978-1-4160-4252-5.50173-8] [Reference Citation Analysis]
351 Wong F. Management of ascites and hepatorenal syndrome. Chronic Inflammation of Liver and Gut 2009. [DOI: 10.1007/978-1-4020-9353-1_19] [Reference Citation Analysis]
352 Berl T, Schrier RW. Vasopressin Antagonists in Physiology and Disease. Textbook of Nephro-Endocrinology 2009. [DOI: 10.1016/b978-0-12-373870-7.00018-1] [Reference Citation Analysis]
353 Andrikos E, Balafa O. Pharmacological Treatment for Hepatorenal Syndrome. Critical Care Nephrology 2009. [DOI: 10.1016/b978-1-4160-4252-5.50204-5] [Reference Citation Analysis]
354 Navarro VJ, Rossi S, Herrine SK. HEPATIC CIRRHOSIS. Pharmacology and Therapeutics 2009. [DOI: 10.1016/b978-1-4160-3291-5.50038-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
355 Somberg JC, Molnar J. Therapeutic Approaches to the Treatment of Edema and Ascites: The Use of Diuretics. American Journal of Therapeutics 2009;16:98-101. [DOI: 10.1097/mjt.0b013e318196082e] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
356 Palma HA, Correa-rotter R. Diálisis peritoneal en situaciones especiales. Tratado de diálisis peritoneal 2009. [DOI: 10.1016/b978-84-8086-394-0.50027-7] [Reference Citation Analysis]
357 Garcia-Tsao G, Parikh CR, Viola A. Acute kidney injury in cirrhosis. Hepatology 2008;48:2064-77. [PMID: 19003880 DOI: 10.1002/hep.22605] [Cited by in Crossref: 438] [Cited by in F6Publishing: 371] [Article Influence: 29.2] [Reference Citation Analysis]
358 Gentilini P, La Villa G. Liver-kidney pathophysiological interrelationships in liver diseases. Dig Liver Dis 2008;40:909-19. [PMID: 18621592 DOI: 10.1016/j.dld.2008.05.013] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
359 Schrier RW. Vasopressin and aquaporin 2 in clinical disorders of water homeostasis. Semin Nephrol 2008;28:289-96. [PMID: 18519089 DOI: 10.1016/j.semnephrol.2008.03.009] [Cited by in Crossref: 55] [Cited by in F6Publishing: 55] [Article Influence: 3.7] [Reference Citation Analysis]
360 Sarin SK, Kumar A, Almeida JA, Chawla YK, Fan ST, Garg H, de Silva HJ, Hamid SS, Jalan R, Komolmit P, Lau GK, Liu Q, Madan K, Mohamed R, Ning Q, Rahman S, Rastogi A, Riordan SM, Sakhuja P, Samuel D, Shah S, Sharma BC, Sharma P, Takikawa Y, Thapa BR, Wai CT, Yuen MF. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the study of the liver (APASL). Hepatol Int 2009;3:269-82. [PMID: 19669378 DOI: 10.1007/s12072-008-9106-x] [Cited by in Crossref: 578] [Cited by in F6Publishing: 626] [Article Influence: 38.5] [Reference Citation Analysis]
361 Huo TI, Lin HC, Hsia CY, Huang YH, Wu JC, Chiang JH, Chiou YY, Lui WY, Lee PC, Lee SD. The MELD-Na is an independent short- and long-term prognostic predictor for hepatocellular carcinoma: a prospective survey. Dig Liver Dis 2008;40:882-9. [PMID: 18339595 DOI: 10.1016/j.dld.2008.01.015] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 2.7] [Reference Citation Analysis]
362 Kim SU, Han KH, Nam CM, Park JY, Kim DY, Chon CY, Ahn SH. Natural history of hepatitis B virus-related cirrhotic patients hospitalized to control ascites. J Gastroenterol Hepatol 2008;23:1722-7. [PMID: 18717757 DOI: 10.1111/j.1440-1746.2008.05510.x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 1.9] [Reference Citation Analysis]
363 Bambha KM, Biggins SW. Inequities of the Model for End-Stage Liver Disease: an examination of current components and future additions. Curr Opin Organ Transplant. 2008;13:227-233. [PMID: 18685308 DOI: 10.1097/MOT.0b013e3282ff84c7] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 1.5] [Reference Citation Analysis]
364 Testro AG, Wongseelashote S, Angus PW, Gow PJ. Long-term outcome of patients treated with terlipressin for types 1 and 2 hepatorenal syndrome. J Gastroenterol Hepatol 2008;23:1535-40. [PMID: 17784863 DOI: 10.1111/j.1440-1746.2007.05176.x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 1.6] [Reference Citation Analysis]
365 Cai C, Chen H, Lu M, Chen G. Model for end-stage liver disease-sodium predicts prognosis in patients with chronic severe hepatitis B: . Chinese Medical Journal 2008;121:2065-9. [DOI: 10.1097/00029330-200810020-00023] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
366 Munoz SJ. The hepatorenal syndrome. Med Clin North Am. 2008;92:813-37, viii-ix. [PMID: 18570944 DOI: 10.1016/j.mcna.2008.03.007] [Cited by in Crossref: 30] [Cited by in F6Publishing: 36] [Article Influence: 2.0] [Reference Citation Analysis]
367 Wong F. Hepatorenal syndrome: current management. Curr Gastroenterol Rep 2008;10:22-9. [PMID: 18417039 DOI: 10.1007/s11894-008-0005-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
368 Kim WR, Biggins SW, Kremers WK, Wiesner RH, Kamath PS, Benson JT, Edwards E, Therneau TM. Hyponatremia and mortality among patients on the liver-transplant waiting list. N Engl J Med. 2008;359:1018-1026. [PMID: 18768945 DOI: 10.1056/nejmoa080120910.1053/jhep.2001.22172] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
369 Kim WR, Biggins SW, Kremers WK, Wiesner RH, Kamath PS, Benson JT, Edwards E, Therneau TM. Hyponatremia and mortality among patients on the liver-transplant waiting list. N Engl J Med. 2008;359:1018-1026. [PMID: 18768945 DOI: 10.1056/nejmoa0801209] [Cited by in Crossref: 877] [Cited by in F6Publishing: 926] [Article Influence: 58.5] [Reference Citation Analysis]
370 Ginès P, Guevara M. Hyponatremia in cirrhosis: pathogenesis, clinical significance, and management. Hepatology 2008;48:1002-10. [PMID: 18671303 DOI: 10.1002/hep.22418] [Cited by in Crossref: 210] [Cited by in F6Publishing: 202] [Article Influence: 14.0] [Reference Citation Analysis]
371 Bonney GK, Aldouri A, Attia M, Lodge PA, Toogood GJ, Pollard SG, Prasad R. Outcomes in right liver lobe transplantation: a matched pair analysis. Transpl Int 2008;21:1045-51. [PMID: 18662370 DOI: 10.1111/j.1432-2277.2008.00722.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.1] [Reference Citation Analysis]
372 Dong MH, Saab S. Complications of cirrhosis. Dis Mon 2008;54:445-56. [PMID: 18570914 DOI: 10.1016/j.disamonth.2008.03.006] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 1.5] [Reference Citation Analysis]
373 Sharma P, Kumar A, Shrama BC, Sarin SK. An open label, pilot, randomized controlled trial of noradrenaline versus terlipressin in the treatment of type 1 hepatorenal syndrome and predictors of response. Am J Gastroenterol 2008;103:1689-97. [PMID: 18557715 DOI: 10.1111/j.1572-0241.2008.01828.x] [Cited by in Crossref: 182] [Cited by in F6Publishing: 190] [Article Influence: 12.1] [Reference Citation Analysis]
374 Mehta RL, Cantarovich F, Shaw A, Hoste E, Murray P. Pharmacologic approaches for volume excess in acute kidney injury (AKI). Int J Artif Organs 2008;31:127-44. [PMID: 18311729 DOI: 10.1177/039139880803100206] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
375 Herrera JL. Complications of Cirrhosis. Practical Management of Liver Diseases 2008. [DOI: 10.1017/cbo9780511547416.014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
376 Carithers RL. Liver Transplantation. Practical Management of Liver Diseases 2008. [DOI: 10.1017/cbo9780511547416.015] [Reference Citation Analysis]
377 Lautrette A, Liotier J, Deteix P, Souweine B. [Hepatorenal syndrome]. Nephrol Ther 2009;5:150-6. [PMID: 18514053 DOI: 10.1016/j.nephro.2008.03.005] [Reference Citation Analysis]
378 Huo TI, Lin HC, Huo SC, Lee PC, Wu JC, Lee FY, Hou MC, Lee SD. Comparison of four model for end-stage liver disease-based prognostic systems for cirrhosis. Liver Transpl 2008;14:837-44. [PMID: 18508377 DOI: 10.1002/lt.21439] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 2.7] [Reference Citation Analysis]
379 Döhler KD, Meyer M. Vasopressin analogues in the treatment of hepatorenal syndrome and gastrointestinal haemorrhage. Best Practice & Research Clinical Anaesthesiology 2008;22:335-50. [DOI: 10.1016/j.bpa.2008.02.002] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 0.7] [Reference Citation Analysis]
380 Cárdenas A, Ginès P. [Dilutional hyponatremia, hepatorenal syndrome and liver transplantation]. Gastroenterol Hepatol. 2008;31:29-36. [PMID: 18218278 DOI: 10.1157/13114568] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
381 Sanyal AJ, Bosch J, Blei A, Arroyo V. Portal hypertension and its complications. Gastroenterology 2008;134:1715-28. [PMID: 18471549 DOI: 10.1053/j.gastro.2008.03.007] [Cited by in Crossref: 245] [Cited by in F6Publishing: 259] [Article Influence: 16.3] [Reference Citation Analysis]
382 Martín-Llahí M, Pépin MN, Guevara M, Díaz F, Torre A, Monescillo A, Soriano G, Terra C, Fábrega E, Arroyo V, Rodés J, Ginès P; TAHRS Investigators. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology 2008;134:1352-9. [PMID: 18471512 DOI: 10.1053/j.gastro.2008.02.024] [Cited by in Crossref: 411] [Cited by in F6Publishing: 436] [Article Influence: 27.4] [Reference Citation Analysis]
383 Lim JK, Groszmann RJ. Vasoconstrictor therapy for the hepatorenal syndrome. Gastroenterology 2008;134:1608-11. [PMID: 18471529 DOI: 10.1053/j.gastro.2008.03.034] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
384 Huo TI, Lee SD, Lin HC. Selecting an optimal prognostic system for liver cirrhosis: the model for end-stage liver disease and beyond. Liver Int 2008;28:606-13. [PMID: 18433390 DOI: 10.1111/j.1478-3231.2008.01727.x] [Cited by in Crossref: 68] [Cited by in F6Publishing: 59] [Article Influence: 4.5] [Reference Citation Analysis]
385 Sanyal AJ, Boyer T, Garcia-Tsao G, Regenstein F, Rossaro L, Appenrodt B, Blei A, Gülberg V, Sigal S, Teuber P; Terlipressin Study Group. A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology 2008;134:1360-8. [PMID: 18471513 DOI: 10.1053/j.gastro.2008.02.014] [Cited by in Crossref: 443] [Cited by in F6Publishing: 469] [Article Influence: 29.5] [Reference Citation Analysis]
386 McCormick PA, Donnelly C. Management of hepatorenal syndrome. Pharmacol Ther. 2008;119:1-6. [PMID: 18539334 DOI: 10.1016/j.pharmthera.2008.02.012] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
387 Manning JJ, Hislop WS, McPeake JR. The management of renal failure in patients with liver disease. Experiences from a district general hospital. Scott Med J 2008;53:25-9. [PMID: 18422206 DOI: 10.1258/RSMSMJ.53.1.25] [Reference Citation Analysis]
388 Genzini T, Torricelli FC. Hepatorenal syndrome: an update. Sao Paulo Med J. 2007;125:50-56. [PMID: 17505686 DOI: 10.1590/S1516-31802007000100010] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 0.7] [Reference Citation Analysis]
389 Angeli P, Merkel C. Pathogenesis and management of hepatorenal syndrome in patients with cirrhosis. J Hepatol 2008;48 Suppl 1:S93-103. [PMID: 18304678 DOI: 10.1016/j.jhep.2008.01.010] [Cited by in Crossref: 78] [Cited by in F6Publishing: 72] [Article Influence: 5.2] [Reference Citation Analysis]
390 Mathur S, Gane EJ, McCall JL, Plank LD. Serum sodium and hydration status predict transplant-free survival independent of MELD score in patients with cirrhosis. J Gastroenterol Hepatol 2008;23:239-43. [PMID: 17489965 DOI: 10.1111/j.1440-1746.2007.04891.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
391 Beckebaum S, Cicinnati V, Frilling A. Pre-Transplantation MAnagement Issue. Liver and Biliary Tract Surgery. [DOI: 10.1007/978-3-211-49277-2_48] [Reference Citation Analysis]
392 Ginès P, Schrier RW. Renal Failure in Cirrhosis. Seldin and Giebisch's The Kidney 2008. [DOI: 10.1016/b978-012088488-9.50082-6] [Reference Citation Analysis]
393 Pépin M, Ginès P. Management of Hepatorenal Syndrome. Therapy in Nephrology & Hypertension 2008. [DOI: 10.1016/b978-141605484-9.50007-1] [Reference Citation Analysis]
394 Schrier RW. Molecular mechanisms of clinical concentrating and diluting disorders. Prog Brain Res 2008;170:539-50. [PMID: 18655907 DOI: 10.1016/S0079-6123(08)00441-X] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
395 Angeli P. Hepatorenal Syndrome. Intensive Care Medicine. [DOI: 10.1007/0-387-35096-9_61] [Reference Citation Analysis]
396 Di Campli C, Zocco MA, Saulnier N, Grieco A, Rapaccini G, Addolorato G, Rumi C, Santoliquido A, Leone G, Gasbarrini G, Gasbarrini A. Safety and efficacy profile of G-CSF therapy in patients with acute on chronic liver failure. Dig Liver Dis 2007;39:1071-6. [PMID: 17964871 DOI: 10.1016/j.dld.2007.08.006] [Cited by in Crossref: 52] [Cited by in F6Publishing: 52] [Article Influence: 3.3] [Reference Citation Analysis]
397 Betrosian AP, Agarwal B, Douzinas EE. Acute renal dysfunction in liver diseases. World J Gastroenterol 2007; 13(42): 5552-5559 [PMID: 17948928 DOI: 10.3748/wjg.v13.i42.5552] [Cited by in CrossRef: 78] [Cited by in F6Publishing: 86] [Article Influence: 4.9] [Reference Citation Analysis]
398 Baccaro ME, Guevara M. [Hepatorenal syndrome]. Gastroenterol Hepatol 2007;30:548-54. [PMID: 17980134 DOI: 10.1157/13111697] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
399 Jacqmin S, Ozier Y, Sogni P. Syndrome hépato-rénal. Le point sur …. [DOI: 10.1007/978-2-287-71152-7_11] [Reference Citation Analysis]
400 Alessandria C, Ottobrelli A, Debernardi-Venon W, Todros L, Cerenzia MT, Martini S, Balzola F, Morgando A, Rizzetto M, Marzano A. Noradrenalin vs terlipressin in patients with hepatorenal syndrome: a prospective, randomized, unblinded, pilot study. J Hepatol 2007;47:499-505. [PMID: 17560680 DOI: 10.1016/j.jhep.2007.04.010] [Cited by in Crossref: 216] [Cited by in F6Publishing: 230] [Article Influence: 13.5] [Reference Citation Analysis]
401 Shusterman B, Mchedishvili G, Rosner MH. Outcomes for hepatorenal syndrome and acute kidney injury in patients undergoing liver transplantation: a single-center experience. Transplant Proc 2007;39:1496-500. [PMID: 17580171 DOI: 10.1016/j.transproceed.2007.01.087] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 0.9] [Reference Citation Analysis]
402 Wong VW, Chim AM, Wong GL, Sung JJ, Chan HL. Performance of the new MELD-Na score in predicting 3-month and 1-year mortality in Chinese patients with chronic hepatitis B. Liver Transpl 2007;13:1228-35. [PMID: 17763399 DOI: 10.1002/lt.21222] [Cited by in Crossref: 45] [Cited by in F6Publishing: 40] [Article Influence: 2.8] [Reference Citation Analysis]
403 Salerno F, Gerbes A, Ginès P, Wong F, Arroyo V. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut 2007;56:1310-8. [PMID: 17389705 DOI: 10.1136/gut.2006.107789] [Cited by in Crossref: 136] [Cited by in F6Publishing: 285] [Article Influence: 8.5] [Reference Citation Analysis]
404 Fernández J, Navasa M, Planas R, Montoliu S, Monfort D, Soriano G, Vila C, Pardo A, Quintero E, Vargas V, Such J, Ginès P, Arroyo V. Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. Gastroenterology 2007;133:818-24. [PMID: 17854593 DOI: 10.1053/j.gastro.2007.06.065] [Cited by in Crossref: 502] [Cited by in F6Publishing: 525] [Article Influence: 31.4] [Reference Citation Analysis]
405 Turban S, Thuluvath PJ, Atta MG. Hepatorenal syndrome. World J Gastroenterol 2007; 13(30): 4046-4055 [PMID: 17696221 DOI: 10.3748/wjg.v13.i30.4046] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 11] [Article Influence: 0.6] [Reference Citation Analysis]
406 Luca A, Angermayr B, Bertolini G, Koenig F, Vizzini G, Ploner M, Peck-Radosavljevic M, Gridelli B, Bosch J. An integrated MELD model including serum sodium and age improves the prediction of early mortality in patients with cirrhosis. Liver Transpl 2007;13:1174-80. [PMID: 17663415 DOI: 10.1002/lt.21197] [Cited by in Crossref: 175] [Cited by in F6Publishing: 165] [Article Influence: 10.9] [Reference Citation Analysis]
407 Dawwas MF, Lewsey JD, Neuberger JM, Gimson AE. The impact of serum sodium concentration on mortality after liver transplantation: a cohort multicenter study. Liver Transpl 2007;13:1115-24. [PMID: 17663412 DOI: 10.1002/lt.21154] [Cited by in Crossref: 95] [Cited by in F6Publishing: 91] [Article Influence: 5.9] [Reference Citation Analysis]
408 Biggins SW. Beyond the numbers: rational and ethical application of outcome models for organ allocation in liver transplantation. Liver Transpl 2007;13:1080-3. [PMID: 17663407 DOI: 10.1002/lt.21210] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
409 Taddei TH, Strazzabosco M. Hepatic venous pressure gradient (HVPG), serum sodium (SNa), and model of end-stage liver disease score (MELD): prognostic significance and correlations. J Clin Gastroenterol 2007;41:641-3. [PMID: 17667045 DOI: 10.1097/MCG.0b013e318051741d] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
410 Gülberg V, Gerbes A. Aszites und hepatorenales Syndrom. Gastroenterologe 2007;2:246-250. [DOI: 10.1007/s11377-007-0087-4] [Reference Citation Analysis]
411 Ruiz R, Barri YM, Jennings LW, Chinnakotla S, Goldstein RM, Levy MF, McKenna GJ, Randall HB, Sanchez EQ, Klintmalm GB. Hepatorenal syndrome: a proposal for kidney after liver transplantation (KALT). Liver Transpl 2007;13:838-43. [PMID: 17539003 DOI: 10.1002/lt.21149] [Cited by in Crossref: 69] [Cited by in F6Publishing: 60] [Article Influence: 4.3] [Reference Citation Analysis]
412 Hardy S, Kleinman RE. Cirrhosis and Chronic Liver Failure. Liver Disease in Children 2007. [DOI: 10.1017/cbo9780511547409.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
413 Grewal P, Martin P. Pretransplant management of the cirrhotic patient. Clin Liver Dis 2007;11:431-49. [PMID: 17606216 DOI: 10.1016/j.cld.2007.04.009] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
414 Tandon P, Bain VG, Tsuyuki RT, Klarenbach S. Systematic review: renal and other clinically relevant outcomes in hepatorenal syndrome trials. Aliment Pharmacol Ther 2007;25:1017-28. [PMID: 17439502 DOI: 10.1111/j.1365-2036.2007.03303.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
415 McCaughan GW, Omata M, Amarapurkar D, Bowden S, Chow WC, Chutaputti A, Dore G, Gane E, Guan R, Hamid SS, Hardikar W, Hui CK, Jafri W, Jia JD, Lai MY, Wei L, Leung N, Piratvisuth T, Sarin S, Sollano J, Tateishi R; Asian Pacific Association for the Study of the Liver (APASL) Hepatitis C Working Party. Asian Pacific Association for the Study of the Liver consensus statements on the diagnosis, management and treatment of hepatitis C virus infection. J Gastroenterol Hepatol 2007;22:615-33. [PMID: 17444847 DOI: 10.1111/j.1440-1746.2007.04883.x] [Cited by in Crossref: 115] [Cited by in F6Publishing: 109] [Article Influence: 7.2] [Reference Citation Analysis]
416 Arroyo V, Terra C, Ginès P. Advances in the pathogenesis and treatment of type-1 and type-2 hepatorenal syndrome. J Hepatol 2007;46:935-46. [PMID: 17391801 DOI: 10.1016/j.jhep.2007.02.001] [Cited by in Crossref: 106] [Cited by in F6Publishing: 100] [Article Influence: 6.6] [Reference Citation Analysis]
417 Besso J, Pru C, Padron J, Plaz J. Hepatorenal Syndrome. Intensive and Critical Care Medicine. [DOI: 10.1007/88-470-0350-4_3] [Reference Citation Analysis]
418 Young AL, Rajagenashan R, Asthana S, Peters CJ, Toogood GJ, Davies MH, Lodge JPA, Pollard SG, Rajendra Prasad K. The value of MELD and sodium in assessing potential liver transplant recipients in the United Kingdom. Transplant Int 2007;20:331-7. [DOI: 10.1111/j.1432-2277.2006.00441.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
419 Baccaro ME, Guevara M, Rodés J. Ascites. The Foundation Years 2007;3:57-60. [DOI: 10.1016/j.mpfou.2007.02.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
420 Kamath PS, Kim WR; Advanced Liver Disease Study Group. The model for end-stage liver disease (MELD). Hepatology 2007;45:797-805. [PMID: 17326206 DOI: 10.1002/hep.21563] [Cited by in Crossref: 1059] [Cited by in F6Publishing: 942] [Article Influence: 66.2] [Reference Citation Analysis]
421 Esrailian E, Pantangco ER, Kyulo NL, Hu KQ, Runyon BA. Octreotide/Midodrine therapy significantly improves renal function and 30-day survival in patients with type 1 hepatorenal syndrome. Dig Dis Sci 2007;52:742-8. [PMID: 17235705 DOI: 10.1007/s10620-006-9312-0] [Cited by in Crossref: 128] [Cited by in F6Publishing: 132] [Article Influence: 8.0] [Reference Citation Analysis]
422 Baccaro ME, Guevara M, Rodés J. Ascites. Medicine 2007;35:104-107. [DOI: 10.1016/j.mpmed.2006.11.005] [Reference Citation Analysis]
423 Cárdenas A, Arroyo V. Management of ascites and hepatic hydrothorax. Best Pract Res Clin Gastroenterol 2007;21:55-75. [PMID: 17223497 DOI: 10.1016/j.bpg.2006.07.012] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 2.1] [Reference Citation Analysis]
424 Moreau R, Lebrec D. Diagnosis and treatment of acute renal failure in patients with cirrhosis. Best Pract Res Clin Gastroenterol 2007;21:111-23. [PMID: 17223500 DOI: 10.1016/j.bpg.2006.10.004] [Cited by in Crossref: 44] [Cited by in F6Publishing: 44] [Article Influence: 2.8] [Reference Citation Analysis]
425 Susla GM, Atkinson AJ. Effect of Liver Disease on Pharmacokinetics. Principles of Clinical Pharmacology. Elsevier; 2007. pp. 73-87. [DOI: 10.1016/b978-012369417-1/50047-x] [Cited by in Crossref: 3] [Article Influence: 0.2] [Reference Citation Analysis]
426 Prieto M, Aguilera V, Berenguer M, Pina R, Benlloch S. Selección de candidatos para trasplante hepático. Gastroenterología y Hepatología 2007;30:42-53. [DOI: 10.1157/13097451] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
427 MacAulay J, Thompson K, Kiberd BA, Barnes DC, Peltekian KM. Serum creatinine in patients with advanced liver disease is of limited value for identification of moderate renal dysfunction: are the equations for estimating renal function better? Can J Gastroenterol. 2006;20:521-526. [PMID: 16955148 DOI: 10.1155/2006/858053] [Cited by in Crossref: 48] [Cited by in F6Publishing: 52] [Article Influence: 2.8] [Reference Citation Analysis]
428 Angeli P, Wong F, Watson H, Ginès P; CAPPS Investigators. Hyponatremia in cirrhosis: Results of a patient population survey. Hepatology 2006;44:1535-42. [PMID: 17133458 DOI: 10.1002/hep.21412] [Cited by in Crossref: 275] [Cited by in F6Publishing: 228] [Article Influence: 16.2] [Reference Citation Analysis]
429 Biggins SW, Colquhoun S, Gish RG, Runyon BA. Model for end-stage liver disease (MELD) exception for ascites. Liver Transpl 2006;12:S88-90. [PMID: 17123288 DOI: 10.1002/lt.20963] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
430 Ahya SN, José Soler M, Levitsky J, Batlle D. Acid-Base and Potassium Disorders in Liver Disease. Seminars in Nephrology 2006;26:466-70. [DOI: 10.1016/j.semnephrol.2006.11.001] [Cited by in Crossref: 33] [Cited by in F6Publishing: 21] [Article Influence: 1.9] [Reference Citation Analysis]
431 Planas R, Montoliu S, Ballesté B, Rivera M, Miquel M, Masnou H, Galeras JA, Giménez MD, Santos J, Cirera I, Morillas RM, Coll S, Solà R. Natural history of patients hospitalized for management of cirrhotic ascites. Clin Gastroenterol Hepatol 2006;4:1385-94. [PMID: 17081806 DOI: 10.1016/j.cgh.2006.08.007] [Cited by in Crossref: 272] [Cited by in F6Publishing: 219] [Article Influence: 16.0] [Reference Citation Analysis]
432 Gluud LL, Kjaer MS, Christensen E. Terlipressin for hepatorenal syndrome. Cochrane Database Syst Rev. 2006;CD005162. [PMID: 17054242 DOI: 10.1002/14651858.cd005162.pub2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 23] [Article Influence: 0.9] [Reference Citation Analysis]
433 Ponte B, Spahr L, Martin P. La prise en charge du syndrome hépato-rénal en réanimation. Le Praticien en Anesthésie Réanimation 2006;10:353-358. [DOI: 10.1016/s1279-7960(06)75605-4] [Reference Citation Analysis]
434 Yu JW, Wang GQ, Li SC. Prediction of the prognosis in patients with acute-on-chronic hepatitis using the MELD scoring system. J Gastroenterol Hepatol 2006;21:1519-24. [PMID: 16928211 DOI: 10.1111/j.1440-1746.2006.04510.x] [Cited by in Crossref: 37] [Cited by in F6Publishing: 31] [Article Influence: 2.2] [Reference Citation Analysis]
435 Fabrizi F, Dixit V, Martin P. Meta-analysis: terlipressin therapy for the hepatorenal syndrome. Aliment Pharmacol Ther 2006;24:935-44. [PMID: 16948805 DOI: 10.1111/j.1365-2036.2006.03086.x] [Cited by in Crossref: 83] [Cited by in F6Publishing: 72] [Article Influence: 4.9] [Reference Citation Analysis]
436 Debray D, Yousef N, Durand P. New management options for end-stage chronic liver disease and acute liver failure: potential for pediatric patients. Paediatr Drugs 2006;8:1-13. [PMID: 16494508 DOI: 10.2165/00148581-200608010-00001] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 1.6] [Reference Citation Analysis]
437 Verma S, Ajudia K, Mendler M, Redeker A. Prevalence of septic events, type 1 hepatorenal syndrome, and mortality in severe alcoholic hepatitis and utility of discriminant function and MELD score in predicting these adverse events. Dig Dis Sci 2006;51:1637-43. [PMID: 16927139 DOI: 10.1007/s10620-006-9099-z] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 2.0] [Reference Citation Analysis]
438 Schepke M, Appenrodt B, Heller J, Zielinski J, Sauerbruch T. Prognostic factors for patients with cirrhosis and kidney dysfunction in the era of MELD: results of a prospective study. Liver Int 2006;26:834-9. [PMID: 16911466 DOI: 10.1111/j.1478-3231.2006.01302.x] [Cited by in Crossref: 42] [Cited by in F6Publishing: 42] [Article Influence: 2.5] [Reference Citation Analysis]
439 Han MK, Hyzy R. Advances in critical care management of hepatic failure and insufficiency: . Critical Care Medicine 2006;34:S225-31. [DOI: 10.1097/01.ccm.0000231882.85350.71] [Cited by in Crossref: 43] [Cited by in F6Publishing: 43] [Article Influence: 2.5] [Reference Citation Analysis]
440 Cárdenas A, Ginès P. Therapy insight: Management of hepatorenal syndrome. Nat Clin Pract Gastroenterol Hepatol. 2006;3:338-348. [PMID: 16741553 DOI: 10.1038/ncpgasthep0517] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 1.2] [Reference Citation Analysis]
441 López-Parra M, Telleria N, Titos E, Planagumà A, González-Périz A, Arroyo V, Rodés J, Clària J. Gene expression profiling of renal dysfunction in rats with experimental cirrhosis. J Hepatol 2006;45:221-9. [PMID: 16644059 DOI: 10.1016/j.jhep.2006.02.019] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
442 Wadei HM, Mai ML, Ahsan N, Gonwa TA. Hepatorenal syndrome: pathophysiology and management. Clin J Am Soc Nephrol. 2006;1:1066-1079. [PMID: 17699328 DOI: 10.2215/cjn.01340406] [Cited by in Crossref: 165] [Cited by in F6Publishing: 184] [Article Influence: 9.7] [Reference Citation Analysis]
443 Rivera-Huizar S, Rincón-Sánchez AR, Covarrubias-Pinedo A, Islas-Carbajal MC, Gabriel-Ortíz G, Pedraza-Chaverrí J, Alvarez-Rodríguez A, Meza-García E, Armendáriz-Borunda J. Renal dysfunction as a consequence of acute liver damage by bile duct ligation in cirrhotic rats. Exp Toxicol Pathol. 2006;58:185-195. [PMID: 16829063 DOI: 10.1016/j.etp.2006.05.001] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 1.6] [Reference Citation Analysis]
444 Chan HL, Chim AM, Lau JT, Hui AY, Wong VW, Sung JJ. Evaluation of model for end-stage liver disease for prediction of mortality in decompensated chronic hepatitis B. Am J Gastroenterol 2006;101:1516-23. [PMID: 16863555 DOI: 10.1111/j.1572-0241.2006.00659.x] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 2.2] [Reference Citation Analysis]
445 Natarajan SK, Basivireddy J, Ramachandran A, Thomas S, Ramamoorthy P, Pulimood AB, Jacob M, Balasubramanian KA. Renal damage in experimentally-induced cirrhosis in rats: Role of oxygen free radicals. Hepatology 2006;43:1248-56. [PMID: 16729302 DOI: 10.1002/hep.21179] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 1.3] [Reference Citation Analysis]
446 Schrier RW. Body water homeostasis: clinical disorders of urinary dilution and concentration. J Am Soc Nephrol. 2006;17:1820-1832. [PMID: 16738014 DOI: 10.1681/asn.2006030240] [Cited by in Crossref: 128] [Cited by in F6Publishing: 137] [Article Influence: 7.5] [Reference Citation Analysis]
447 Sandhu BS, Sanyal AJ. Hepatorenal syndrome. Curr Treat Options Gastroenterol 2005;8:443-50. [PMID: 16313861 DOI: 10.1007/s11938-005-0030-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
448 Biggins SW, Kim WR, Terrault NA, Saab S, Balan V, Schiano T, Benson J, Therneau T, Kremers W, Wiesner R, Kamath P, Klintmalm G. Evidence-based incorporation of serum sodium concentration into MELD. Gastroenterology 2006;130:1652-60. [PMID: 16697729 DOI: 10.1053/j.gastro.2006.02.010] [Cited by in Crossref: 487] [Cited by in F6Publishing: 513] [Article Influence: 28.6] [Reference Citation Analysis]
449 Cárdenas A, Gines P. Hepatorenal syndrome. Clin Liver Dis 2006;10:371-85, ix-x. [PMID: 16971267 DOI: 10.1016/j.cld.2006.05.006] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 0.8] [Reference Citation Analysis]
450 Londoño MC, Guevara M, Rimola A, Navasa M, Taurà P, Mas A, García-Valdecasas JC, Arroyo V, Ginès P. Hyponatremia impairs early posttransplantation outcome in patients with cirrhosis undergoing liver transplantation. Gastroenterology 2006;130:1135-43. [PMID: 16618408 DOI: 10.1053/j.gastro.2006.02.017] [Cited by in Crossref: 139] [Cited by in F6Publishing: 145] [Article Influence: 8.2] [Reference Citation Analysis]
451 Chiu A, Fan ST. Use of MARS in Hepatorenal Syndrome — A Local Perspective. Hong Kong Journal of Nephrology 2006;8:5-9. [DOI: 10.1016/s1561-5413(09)60223-4] [Reference Citation Analysis]
452 Bernal W, Wendon J. Cell-Free Artificial Liver Support: Design of Appropriate Clinical Studies. Therapher Dial 2006;10:175-9. [DOI: 10.1111/j.1744-9987.2006.00360.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
453 Esrailian E, Runyon BA. Alcoholic cirrhosis-associated hepatorenal syndrome treated with vasoactive agents. Nat Rev Nephrol 2006;2:169-72. [DOI: 10.1038/ncpneph0114] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
454 Moreau R, Lebrec D. The use of vasoconstrictors in patients with cirrhosis: type 1 HRS and beyond. Hepatology 2006;43:385-94. [PMID: 16496352 DOI: 10.1002/hep.21094] [Cited by in Crossref: 102] [Cited by in F6Publishing: 89] [Article Influence: 6.0] [Reference Citation Analysis]
455 Brünnler T, Mandraka F, Langgartner J. Terlipressin—. Intensivmed 2006;43:82-82. [DOI: 10.1007/s00390-006-0691-4] [Reference Citation Analysis]
456 Biancofiore G, Pucci L, Cerutti E, Penno G, Pardini E, Esposito M, Bindi L, Pelati E, Romanelli A, Triscornia S, Salvadorini MP, Stratta C, Lanfranco G, Pellegrini G, Del Prato S, Salizzoni M, Mosca F, Filipponi F. Cystatin C as a marker of renal function immediately after liver transplantation. Liver Transpl 2006;12:285-91. [PMID: 16447198 DOI: 10.1002/lt.20657] [Cited by in Crossref: 43] [Cited by in F6Publishing: 42] [Article Influence: 2.5] [Reference Citation Analysis]
457 Sargent S. The management and nursing care of cirrhotic ascites. British Journal of Nursing 2006;15:212-9. [DOI: 10.12968/bjon.2006.15.4.20547] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
458 Di Campli C, Santoro MC, Gaspari R, Merra G, Zileri Dal Verme L, Zocco MA, Piscaglia AC, Di Gioacchino G, Novi M, Santoliquido A. Catholic university experience with molecular adsorbent recycling system in patients with severe liver failure. Transplant Proc. 2005;37:2547-2550. [PMID: 16182739 DOI: 10.1016/j.transproceed.2005.06.048] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 0.9] [Reference Citation Analysis]
459 Hepatorenal syndrome. Hepatology Principles and Practice. [DOI: 10.1007/3-540-28977-1_17] [Reference Citation Analysis]
460 Demırtaş S, Can M, Yarpuzlu A. Hepatorenal syndrome / Hepatorenales Syndrom. LaboratoriumsMedizin 2006;30:272-279. [DOI: 10.1515/jlm.2006.998] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
461 Pillebout E. Syndrome hépatorénal. EMC - Néphrologie 2006;1:1-7. [DOI: 10.1016/s1762-0945(11)58254-3] [Reference Citation Analysis]
462 Garcia-tsao G. Ascites. Zakim and Boyer's Hepatology 2006. [DOI: 10.1016/b978-1-4160-3258-8.50024-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
463 Sargent S, Martin W. Renal dysfunction in liver cirrhosis. Br J Nurs 2006;15:12-16. [DOI: 10.12968/bjon.2006.15.1.20302] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
464 Angeli P, Guarda S, Fasolato S, Miola E, Craighero R, Piccolo F, Antona C, Brollo L, Franchin M, Cillo U, Merkel C, Gatta A. Switch therapy with ciprofloxacin vs. intravenous ceftazidime in the treatment of spontaneous bacterial peritonitis in patients with cirrhosis: similar efficacy at lower cost. Aliment Pharmacol Ther 2006;23:75-84. [PMID: 16393283 DOI: 10.1111/j.1365-2036.2006.02706.x] [Cited by in Crossref: 52] [Cited by in F6Publishing: 48] [Article Influence: 3.1] [Reference Citation Analysis]
465 Arroyo V, Ginès P, Guevara M, Rodés J. Renal Dysfunction in Cirrhosis: Pathophysiology, Clinical Features and Therapy. Zakim and Boyer's Hepatology 2006. [DOI: 10.1016/b978-1-4160-3258-8.50027-9] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
466 Angeli P. Hepatorenal Syndrome. Yearbook of Intensive Care and Emergency Medicine 2006. [DOI: 10.1007/3-540-33396-7_61] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
467 Péron JM, Bureau C, Gonzalez L, Garcia-Ricard F, de Soyres O, Dupuis E, Alric L, Pourrat J, Vinel JP. Treatment of hepatorenal syndrome as defined by the international ascites club by albumin and furosemide infusion according to the central venous pressure: a prospective pilot study. Am J Gastroenterol 2005;100:2702-7. [PMID: 16393223 DOI: 10.1111/j.1572-0241.2005.00271.x] [Cited by in Crossref: 43] [Cited by in F6Publishing: 42] [Article Influence: 2.4] [Reference Citation Analysis]
468 Terra C, Guevara M, Torre A, Gilabert R, Fernández J, Martín-Llahí M, Baccaro ME, Navasa M, Bru C, Arroyo V, Rodés J, Ginès P. Renal failure in patients with cirrhosis and sepsis unrelated to spontaneous bacterial peritonitis: value of MELD score. Gastroenterology 2005;129:1944-53. [PMID: 16344063 DOI: 10.1053/j.gastro.2005.09.024] [Cited by in Crossref: 185] [Cited by in F6Publishing: 197] [Article Influence: 10.3] [Reference Citation Analysis]
469 Bloom RD, Goldberg LR, Wang AY, Faust TW, Kotloff RM. An Overview of Solid Organ Transplantation. Clinics in Chest Medicine 2005;26:529-43. [DOI: 10.1016/j.ccm.2005.06.002] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 1.2] [Reference Citation Analysis]
470 Mendez CM, McClain CJ, Marsano LS. Albumin therapy in clinical practice. Nutr Clin Pract 2005;20:314-20. [PMID: 16207669 DOI: 10.1177/0115426505020003314] [Cited by in Crossref: 107] [Cited by in F6Publishing: 112] [Article Influence: 5.9] [Reference Citation Analysis]
471 Marik PE, Wood K, Starzl TE. The course of type 1 hepato-renal syndrome post liver transplantation. Nephrol Dial Transplant. 2006;21:478-482. [PMID: 16249201 DOI: 10.1093/ndt/gfi212] [Cited by in Crossref: 110] [Cited by in F6Publishing: 118] [Article Influence: 6.1] [Reference Citation Analysis]
472 Howard CS, Teitelbaum I. Renal replacement therapy in patients with chronic liver disease. Semin Dial. 2005;18:212-216. [PMID: 15934968 DOI: 10.1111/j.1525-139x.2005.18315.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.1] [Reference Citation Analysis]
473 Wright AS, Rikkers LF. Current management of portal hypertension. J Gastrointest Surg 2005;9:992-1005. [PMID: 16137597 DOI: 10.1016/j.gassur.2004.09.028] [Cited by in Crossref: 51] [Cited by in F6Publishing: 56] [Article Influence: 2.8] [Reference Citation Analysis]
474 Ruiz-del-Arbol L, Monescillo A, Arocena C, Valer P, Ginès P, Moreira V, Milicua JM, Jiménez W, Arroyo V. Circulatory function and hepatorenal syndrome in cirrhosis. Hepatology 2005;42:439-47. [PMID: 15977202 DOI: 10.1002/hep.20766] [Cited by in Crossref: 407] [Cited by in F6Publishing: 340] [Article Influence: 22.6] [Reference Citation Analysis]
475 Zaza S, Bonny O, Liaudet L. Le syndrome hépatorénal chez le patient cirrhotique. Néphrologie & Thérapeutique 2005;1:174-82. [DOI: 10.1016/j.nephro.2005.03.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.1] [Reference Citation Analysis]
476 Kiser TH, Fish DN, Obritsch MD, Jung R, MacLaren R, Parikh CR. Vasopressin, not octreotide, may be beneficial in the treatment of hepatorenal syndrome: a retrospective study. Nephrol Dial Transplant 2005;20:1813-20. [PMID: 15956066 DOI: 10.1093/ndt/gfh930] [Cited by in Crossref: 60] [Cited by in F6Publishing: 67] [Article Influence: 3.3] [Reference Citation Analysis]
477 Murray KF, Carithers RL Jr; AASLD. AASLD practice guidelines: Evaluation of the patient for liver transplantation. Hepatology 2005;41:1407-32. [PMID: 15880505 DOI: 10.1002/hep.20704] [Cited by in Crossref: 553] [Cited by in F6Publishing: 496] [Article Influence: 30.7] [Reference Citation Analysis]
478 Brünnler T, Mandraka F, Langgartner J. Terlipressin—. Intensivmed 2005;42:468-478. [DOI: 10.1007/s00390-005-0603-z] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
479 Alessandria C, Ozdogan O, Guevara M, Restuccia T, Jiménez W, Arroyo V, Rodés J, Ginès P. MELD score and clinical type predict prognosis in hepatorenal syndrome: relevance to liver transplantation. Hepatology 2005;41:1282-9. [PMID: 15834937 DOI: 10.1002/hep.20687] [Cited by in Crossref: 261] [Cited by in F6Publishing: 230] [Article Influence: 14.5] [Reference Citation Analysis]
480 Pham PT, Pham PC, Rastogi A, Wilkinson AH. Review article: current management of renal dysfunction in the cirrhotic patient. Aliment Pharmacol Ther 2005;21:949-61. [PMID: 15813830 DOI: 10.1111/j.1365-2036.2005.02357.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 1.8] [Reference Citation Analysis]
481 Capling RK, Bastani B. The clinical course of patients with type 1 hepatorenal syndrome maintained on hemodialysis. Ren Fail. 2004;26:563-568. [PMID: 15526916 DOI: 10.1081/jdi-200035988] [Cited by in Crossref: 42] [Cited by in F6Publishing: 45] [Article Influence: 2.3] [Reference Citation Analysis]
482 Vaughan RB, Chin-dusting JP. Current pharmacotherapy in the management of cirrhosis: focus on the hyperdynamic circulation. Expert Opinion on Pharmacotherapy 2005;4:625-37. [DOI: 10.1517/14656566.4.5.625] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
483 Ruf AE, Kremers WK, Chavez LL, Descalzi VI, Podesta LG, Villamil FG. Addition of serum sodium into the MELD score predicts waiting list mortality better than MELD alone. Liver Transpl 2005;11:336-43. [PMID: 15719386 DOI: 10.1002/lt.20329] [Cited by in Crossref: 305] [Cited by in F6Publishing: 234] [Article Influence: 16.9] [Reference Citation Analysis]
484 Nietsch HH. Management of portal hypertension. J Clin Gastroenterol 2005;39:232-6. [PMID: 15718866 DOI: 10.1097/01.mcg.0000152783.22266.35] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
485 Henriksen JH. Volume adaptation in chronic liver disease: on the static and dynamic location of water, salt, protein and red cells in cirrhosis. Scand J Clin Lab Invest. 2004;64:523-533. [PMID: 15370457 DOI: 10.1080/00365510410002788] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
486 Cárdenas A. Hepatorenal syndrome: a dreaded complication of end-stage liver disease. Am J Gastroenterol 2005;100:460-7. [PMID: 15667508 DOI: 10.1111/j.1572-0241.2005.40952.x] [Cited by in Crossref: 58] [Cited by in F6Publishing: 60] [Article Influence: 3.2] [Reference Citation Analysis]
487 Liotier J, Souweine B, Deteix P. Syndrome hépatorénal. EMC - Néphrologie 2005;2:1-7. [DOI: 10.1016/j.emcnep.2004.11.001] [Reference Citation Analysis]
488 Sonoda J, Chong LW, Downes M, Barish GD, Coulter S, Liddle C, Lee CH, Evans RM. Pregnane X receptor prevents hepatorenal toxicity from cholesterol metabolites. Proc Natl Acad Sci U S A 2005;102:2198-203. [PMID: 15671183 DOI: 10.1073/pnas.0409481102] [Cited by in Crossref: 63] [Cited by in F6Publishing: 70] [Article Influence: 3.5] [Reference Citation Analysis]
489 Gluud L, Kjaer M, Taastroem A, Christensen E. Terlipressin for hepatorenal syndrome. Cochrane Database of Systematic Reviews 2005. [DOI: 10.1002/14651858.cd005162] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
490 Sharma P, Vargas HE, Rakela J. Monitoring and Care of the Patient Before Liver Transplantation. Transplantation of the Liver 2005. [DOI: 10.1016/b978-0-7216-0118-2.50037-9] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
491 Guevara M, Ginès P. Hepatorenal syndrome. Dig Dis 2005;23:47-55. [PMID: 15920325 DOI: 10.1159/000084725] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 1.4] [Reference Citation Analysis]
492 Mai ML, Yip DS, Keller CA, Gonwa TA. Pretransplantation Evaluation: Pulmonary, Cardiac, and Renal. Transplantation of the Liver 2005. [DOI: 10.1016/b978-0-7216-0118-2.50033-1] [Reference Citation Analysis]
493 Kbalid SK, Garcia-tsao G. Ascites. Portal Hypertension 2005. [DOI: 10.1007/978-1-59259-885-4_19] [Reference Citation Analysis]
494 Bergheim I, McClain CJ, Arteel GE. Treatment of alcoholic liver disease. Dig Dis 2005;23:275-84. [PMID: 16508292 DOI: 10.1159/000090175] [Cited by in Crossref: 54] [Cited by in F6Publishing: 56] [Article Influence: 3.0] [Reference Citation Analysis]
495 Pham PT, Pham PT, Wilkinson AH. Renal Failure in Adult Liver Transplant Recipients. Transplantation of the Liver. Elsevier; 2005. pp. 891-914. [DOI: 10.1016/b978-0-7216-0118-2.50065-3] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
496 Veis JH. Alcohol, Alcoholism and Effects on the Kidney and Kidney Disease. Comprehensive Handbook of Alcohol Related Pathology 2005. [DOI: 10.1016/b978-012564370-2/50043-x] [Reference Citation Analysis]
497 Moore K. Diagnosis and Management of the Hepatorenal Syndrome. Portal Hypertension 2005. [DOI: 10.1007/978-1-59259-885-4_22] [Reference Citation Analysis]
498 Biggins SW, Rodriguez HJ, Bacchetti P, Bass NM, Roberts JP, Terrault NA. Serum sodium predicts mortality in patients listed for liver transplantation. Hepatology 2005;41:32-9. [PMID: 15690479 DOI: 10.1002/hep.20517] [Cited by in Crossref: 299] [Cited by in F6Publishing: 229] [Article Influence: 16.6] [Reference Citation Analysis]
499 Cardenas A, Ginès P. Management of complications of cirrhosis in patients awaiting liver transplantation. J Hepatol 2005;42 Suppl:S124-33. [PMID: 15777567 DOI: 10.1016/j.jhep.2004.12.007] [Cited by in Crossref: 46] [Cited by in F6Publishing: 43] [Article Influence: 2.4] [Reference Citation Analysis]
500 Serra MA, Puchades MJ, Rodríguez F, Escudero A, del Olmo JA, Wassel AH, Rodrigo JM. Clinical value of increased serum creatinine concentration as predictor of short-term outcome in decompensated cirrhosis. Scand J Gastroenterol 2004;39:1149-53. [PMID: 15545175 DOI: 10.1080/00365520410008024] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.5] [Reference Citation Analysis]
501 Heuman DM, Abou-Assi SG, Habib A, Williams LM, Stravitz RT, Sanyal AJ, Fisher RA, Mihas AA. Persistent ascites and low serum sodium identify patients with cirrhosis and low MELD scores who are at high risk for early death. Hepatology 2004;40:802-10. [PMID: 15382176 DOI: 10.1002/hep.20405] [Cited by in Crossref: 35] [Cited by in F6Publishing: 97] [Article Influence: 1.8] [Reference Citation Analysis]
502 Heuman DM, Abou-Assi SG, Habib A, Williams LM, Stravitz RT, Sanyal AJ, Fisher RA, Mihas AA. Persistent ascites and low serum sodium identify patients with cirrhosis and low MELD scores who are at high risk for early death. Hepatology 2004;40:802-10. [PMID: 15382176 DOI: 10.1002/hep.20405] [Cited by in Crossref: 376] [Cited by in F6Publishing: 267] [Article Influence: 19.8] [Reference Citation Analysis]
503 Girón-González JA, Martínez-Sierra C, Rodriguez-Ramos C, Macías MA, Rendón P, Díaz F, Fernández-Gutiérrez C, Martín-Herrera L. Implication of inflammation-related cytokines in the natural history of liver cirrhosis. Liver Int 2004;24:437-45. [PMID: 15482340 DOI: 10.1111/j.1478-3231.2004.0951.x] [Cited by in Crossref: 67] [Cited by in F6Publishing: 63] [Article Influence: 3.5] [Reference Citation Analysis]
504 Angeli P. Review article: prognosis of hepatorenal syndrome--has it changed with current practice? Aliment Pharmacol Ther 2004;20 Suppl 3:44-6; discussion 47-8. [PMID: 15335400 DOI: 10.1111/j.1365-2036.2004.02113.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
505 Sen S, Williams R, Jalan R. The pathophysiological basis of acute-on-chronic liver failure. Liver 2002;22 Suppl 2:5-13. [PMID: 12220296 DOI: 10.1034/j.1600-0676.2002.00001.x] [Cited by in Crossref: 217] [Cited by in F6Publishing: 190] [Article Influence: 11.4] [Reference Citation Analysis]
506 Moreau R, Lebrec D. Review article: hepatorenal syndrome--definitions and diagnosis. Aliment Pharmacol Ther 2004;20 Suppl 3:24-8; discussion 29-30. [PMID: 15335396 DOI: 10.1111/j.1365-2036.2004.02111.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
507 Arroyo V. Review article: hepatorenal syndrome--how to assess response to treatment and nonpharmacological therapy. Aliment Pharmacol Ther 2004;20 Suppl 3:49-54; discussion 55-6. [PMID: 15335402 DOI: 10.1111/j.1365-2036.2004.02114.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
508 Wong F, Pantea L, Sniderman K. Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology 2004;40:55-64. [PMID: 15239086 DOI: 10.1002/hep.20262] [Cited by in Crossref: 271] [Cited by in F6Publishing: 236] [Article Influence: 14.3] [Reference Citation Analysis]
509 Alessandria C, Gaia S, Marzano A, Venon WD, Fadda M, Rizzetto M. Application of the model for end-stage liver disease score for transjugular intrahepatic portosystemic shunt in cirrhotic patients with refractory ascites and renal impairment. Eur J Gastroenterol Hepatol 2004;16:607-12. [PMID: 15167164 DOI: 10.1097/00042737-200406000-00015] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
510 Gonzlez Garca M, Ruiz del rbol Olmos L, Albillos Martnez A. Ascitis y s?ndrome hepatorrenal. Medicine - Programa de Formaci?n M?dica Continuada Acreditado 2004;9:504-512. [DOI: 10.1016/s0211-3449(04)70065-x] [Reference Citation Analysis]
511 De Lédinghen V. Traitement du syndrome hépato-rénal. Gastroentérologie Clinique et Biologique 2004;28:130-137. [DOI: 10.1016/s0399-8320(04)95248-7] [Reference Citation Analysis]
512 Kramer L, Druml W. Ascites and intraabdominal infection: . Current Opinion in Critical Care 2004;10:146-51. [DOI: 10.1097/00075198-200404000-00011] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
513 Duvoux C. Comment traiter un syndrome hépato-rénal. Gastroentérologie Clinique et Biologique 2004;28:270-277. [DOI: 10.1016/s0399-8320(04)95266-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
514 Sansoé G, Silvano S, Mengozzi G, Todros L, Smedile A, Touscoz G, Rosina F, Rizzetto M. Inappropriately low angiotensin II generation: a factor determining reduced kidney function and survival in patients with decompensated cirrhosis. J Hepatol 2004;40:417-23. [PMID: 15123355 DOI: 10.1016/j.jhep.2003.11.010] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 0.6] [Reference Citation Analysis]
515 Ginès P, Guevara M, Arroyo V, Rodés J. Hepatorenal syndrome. Lancet. 2003;362:1819-1827. [PMID: 14654322 DOI: 10.1016/s0140-6736(03)14903-3] [Cited by in Crossref: 434] [Cited by in F6Publishing: 464] [Article Influence: 22.8] [Reference Citation Analysis]
516 Rössle M, Grandt D. TIPS: an update. Best Pract Res Clin Gastroenterol 2004;18:99-123. [PMID: 15123087 DOI: 10.1016/j.bpg.2003.08.004] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 1.2] [Reference Citation Analysis]
517 Moreau R. The growing evidence that renal function should be improved in patients with cirrhosis and hepatorenal syndrome before liver transplantation. J Hepatol 2004;40:159-61. [PMID: 14672628 DOI: 10.1016/j.jhep.2003.10.024] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 0.7] [Reference Citation Analysis]
518 Sivayokan T, Dillon JF. Cirrhotic ascites: a review of management. Hospital Medicine 2004;65:22-6. [DOI: 10.12968/hosp.2004.65.1.2414] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
519 Wong F. Complications of Cirrhosis: Ascites and Spontaneous Bacterial Peritonitis. Atlas of the Liver 2004. [DOI: 10.1007/978-1-4615-6502-4_10] [Reference Citation Analysis]
520 Tran TT, Martin P. Liver Transplantation. Atlas of the Liver 2004. [DOI: 10.1007/978-1-4615-6502-4_14] [Reference Citation Analysis]
521 Vaccaro F, Giorgi A, Riggio O, De Santis A, Laviano A, Rossi-Fanelli F. Is spontaneous bacterial peritonitis an inducer of vasopressin analogue side-effects? A case report. Dig Liver Dis 2003;35:503-6. [PMID: 12870738 DOI: 10.1016/s1590-8658(03)00225-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
522 Pomier-Layrargues G, Paquin SC, Hassoun Z, Lafortune M, Tran A. Octreotide in hepatorenal syndrome: a randomized, double-blind, placebo-controlled, crossover study. Hepatology 2003;38:238-43. [PMID: 12830007 DOI: 10.1053/jhep.2003.50276] [Cited by in Crossref: 102] [Cited by in F6Publishing: 93] [Article Influence: 5.1] [Reference Citation Analysis]
523 Aguillon D, Seguin P, Mallédant Y. [Hepatorenal syndrome: from physiopathology to treatment]. Ann Fr Anesth Reanim. 2003;22:30-38. [PMID: 12738017 DOI: 10.1016/S0750-7658(02)00851-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
524 Sen S, Williams R, Jalan R. The pathophysiological basis of acute-on-chronic liver failure. Liver. 2002;22 Suppl 2:5-13. [PMID: 12220296 DOI: 10.1034/j.1600-0676.2002.00001.x] [Cited by in Crossref: 132] [Cited by in F6Publishing: 147] [Article Influence: 6.6] [Reference Citation Analysis]
525 Guevara M. [Treatment of hepatorenal syndrome]. Gastroenterol Hepatol 2003;26:270-4. [PMID: 12681123 DOI: 10.1016/s0210-5705(03)70353-7] [Reference Citation Analysis]
526 Gerbes AL, Gülberg V, Ginès P, Decaux G, Gross P, Gandjini H, Djian J; VPA Study Group. Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double-blind multicenter trial. Gastroenterology 2003;124:933-9. [PMID: 12671890 DOI: 10.1053/gast.2003.50143] [Cited by in Crossref: 227] [Cited by in F6Publishing: 241] [Article Influence: 11.4] [Reference Citation Analysis]
527 N/A. N/A. Shijie Huaren Xiaohua Zazhi 2003; 11(3): 330-333 [DOI: 10.11569/wcjd.v11.i3.330] [Reference Citation Analysis]
528 Moreau R, Lebrec D. Acute renal failure in patients with cirrhosis: perspectives in the age of MELD. Hepatology 2003;37:233-43. [PMID: 12540770 DOI: 10.1053/jhep.2003.50084] [Cited by in Crossref: 179] [Cited by in F6Publishing: 153] [Article Influence: 9.0] [Reference Citation Analysis]
529 Solanki P, Chawla A, Garg R, Gupta R, Jain M, Sarin SK. Beneficial effects of terlipressin in hepatorenal syndrome: a prospective, randomized placebo-controlled clinical trial. J Gastroenterol Hepatol 2003;18:152-6. [PMID: 12542598 DOI: 10.1046/j.1440-1746.2003.02934.x] [Cited by in Crossref: 203] [Cited by in F6Publishing: 196] [Article Influence: 10.2] [Reference Citation Analysis]
530 Cárdenas A, Sánchez-fueyo A. Disfunción circulatoria en la cirrosis. Fisiopatología y consecuencias clínicas. Gastroenterología y Hepatología 2003;26:447-455. [DOI: 10.1016/s0210-5705(03)70388-4] [Reference Citation Analysis]
531 Dancygier H, Nagell W. Leberzirrhose und Folgeerkrankungen. Klinische Hepatologie 2003. [DOI: 10.1007/978-3-642-55902-0_27] [Reference Citation Analysis]
532 Cassinello C, Moreno E, Gozalo A, Ortuño B, Cuenca B, Solís-Herruzo JA. Effects of orthotopic liver transplantation on vasoactive systems and renal function in patients with advanced liver cirrhosis. Dig Dis Sci 2003;48:179-86. [PMID: 12645807 DOI: 10.1023/a:1021763221337] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 1.8] [Reference Citation Analysis]
533 Arroyo V, Colmenero J. Ascites and hepatorenal syndrome in cirrhosis: pathophysiological basis of therapy and current management. J Hepatol 2003;38 Suppl 1:S69-89. [PMID: 12591187 DOI: 10.1016/s0168-8278(03)00007-2] [Cited by in Crossref: 196] [Cited by in F6Publishing: 195] [Article Influence: 9.8] [Reference Citation Analysis]
534 Dancygier H. Aszites. Klinische Hepatologie 2003. [DOI: 10.1007/978-3-642-55902-0_19] [Reference Citation Analysis]
535 Prieto M, Clemente G, Casafont F, Cuende N, Cuervas-mons V, Figueras J, Grande L, Herrero J, Jara P, Mas A, de la Matak M, Navasa M. Documento de consenso de indicaciones de trasplante hepático. Gastroenterología y Hepatología 2003;26:355-75. [DOI: 10.1016/s0210-5705(03)70373-2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
536 Alessandria C, Venon WD, Marzano A, Barletti C, Fadda M, Rizzetto M. Renal failure in cirrhotic patients: role of terlipressin in clinical approach to hepatorenal syndrome type 2. Eur J Gastroenterol Hepatol 2002;14:1363-8. [PMID: 12468959 DOI: 10.1097/00042737-200212000-00013] [Cited by in Crossref: 109] [Cited by in F6Publishing: 107] [Article Influence: 5.2] [Reference Citation Analysis]
537 Henriksen JH, Kiszka-Kanowitz M, Bendtsen F. Review article: volume expansion in patients with cirrhosis. Aliment Pharmacol Ther 2002;16 Suppl 5:12-23. [PMID: 12423449 DOI: 10.1046/j.1365-2036.16.s5.3.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 1.5] [Reference Citation Analysis]
538 Briglia AE, Anania FA. Hepatorenal syndrome. Definition, pathophysiology, and intervention. Crit Care Clin 2002;18:345-73. [PMID: 12053838 DOI: 10.1016/s0749-0704(01)00003-3] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
539 Cheng IK. Hepatorenal syndrome. Hong Kong Journal of Nephrology 2002;4:78-86. [DOI: 10.1016/s1561-5413(09)60084-3] [Reference Citation Analysis]
540 Ortega R, Ginès P, Uriz J, Cárdenas A, Calahorra B, De Las Heras D, Guevara M, Bataller R, Jiménez W, Arroyo V, Rodés J. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study. Hepatology 2002;36:941-8. [PMID: 12297842 DOI: 10.1053/jhep.2002.35819] [Cited by in Crossref: 375] [Cited by in F6Publishing: 337] [Article Influence: 17.9] [Reference Citation Analysis]
541 Duvoux C, Zanditenas D, Hézode C, Chauvat A, Monin JL, Roudot-Thoraval F, Mallat A, Dhumeaux D. Effects of noradrenalin and albumin in patients with type I hepatorenal syndrome: a pilot study. Hepatology 2002;36:374-80. [PMID: 12143045 DOI: 10.1053/jhep.2002.34343] [Cited by in Crossref: 260] [Cited by in F6Publishing: 232] [Article Influence: 12.4] [Reference Citation Analysis]
542 Subramanian RM, Sorrell MF. The hepatorenal syndrome: a continuing challenge. Am J Gastroenterol 2002;97:1868-70. [PMID: 12190146 DOI: 10.1111/j.1572-0241.2002.05896.x] [Reference Citation Analysis]
543 Colle I, Durand F, Pessione F, Rassiat E, Bernuau J, Barrière E, Lebrec D, Valla DC, Moreau R. Clinical course, predictive factors and prognosis in patients with cirrhosis and type 1 hepatorenal syndrome treated with Terlipressin: a retrospective analysis. J Gastroenterol Hepatol 2002;17:882-8. [PMID: 12164964 DOI: 10.1046/j.1440-1746.2002.02816.x] [Cited by in Crossref: 108] [Cited by in F6Publishing: 98] [Article Influence: 5.1] [Reference Citation Analysis]
544 Watt K, Uhanova J, Minuk GY. Hepatorenal syndrome: diagnostic accuracy, clinical features, and outcome in a tertiary care center. Am J Gastroenterol 2002;97:2046-50. [PMID: 12190175 DOI: 10.1111/j.1572-0241.2002.05920.x] [Cited by in Crossref: 40] [Cited by in F6Publishing: 39] [Article Influence: 1.9] [Reference Citation Analysis]
545 Ginès P, Guevara M. Good news for hepatorenal syndrome. Hepatology 2002;36:504-6. [PMID: 12143062 DOI: 10.1053/jhep.2002.35273] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 0.5] [Reference Citation Analysis]
546 Brensing KA, Raab P, Textor J, Görich J, Schiedermaier P, Strunk H, Paar D, Schepke M, Sudhop T, Spengler U, Schild H, Sauerbruch T. Prospective evaluation of a clinical score for 60-day mortality after transjugular intrahepatic portosystemic stent-shunt: Bonn TIPSS early mortality analysis. Eur J Gastroenterol Hepatol 2002;14:723-31. [PMID: 12169980 DOI: 10.1097/00042737-200207000-00003] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 1.6] [Reference Citation Analysis]
547 Moreau R. Hepatorenal syndrome in patients with cirrhosis. J Gastroenterol Hepatol 2002;17:739-47. [PMID: 12121502 DOI: 10.1046/j.1440-1746.2002.02778.x] [Cited by in Crossref: 46] [Cited by in F6Publishing: 43] [Article Influence: 2.2] [Reference Citation Analysis]
548 Kramer L, Hörl WH. Hepatorenal syndrome. Seminars in Nephrology 2002;22:290-301. [DOI: 10.1053/snep.2002.33670] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 1.0] [Reference Citation Analysis]
549 Arroyo V, Guevara M, Ginès P. Hepatorenal syndrome in cirrhosis: pathogenesis and treatment. Gastroenterology 2002;122:1658-76. [PMID: 12016430 DOI: 10.1053/gast.2002.33575] [Cited by in Crossref: 107] [Cited by in F6Publishing: 113] [Article Influence: 5.1] [Reference Citation Analysis]
550 Moreau R, Durand F, Poynard T, Duhamel C, Cervoni JP, Ichaï P, Abergel A, Halimi C, Pauwels M, Bronowicki JP, Giostra E, Fleurot C, Gurnot D, Nouel O, Renard P, Rivoal M, Blanc P, Coumaros D, Ducloux S, Levy S, Pariente A, Perarnau JM, Roche J, Scribe-Outtas M, Valla D, Bernard B, Samuel D, Butel J, Hadengue A, Platek A, Lebrec D, Cadranel JF. Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study. Gastroenterology 2002;122:923-30. [PMID: 11910344 DOI: 10.1053/gast.2002.32364] [Cited by in Crossref: 323] [Cited by in F6Publishing: 345] [Article Influence: 15.4] [Reference Citation Analysis]
551 Cárdenas A, Arroyo V. Hepatorenal syndrome-pathogenesis and treatment. Curr Gastroenterol Rep 2002;4:1-4. [PMID: 11825535 DOI: 10.1007/s11894-002-0029-8] [Reference Citation Analysis]
552 Mullen KD. Treatment of hepatorenal syndrome: lessons from the MARS trial. Hepatology 2002;35:492-3. [PMID: 11826426 DOI: 10.1053/jhep.2002.0350492] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
553 Halimi C, Bonnard P, Bernard B, Mathurin P, Mofredj A, di Martino V, Demontis R, Henry-Biabaud E, Fievet P, Opolon P, Poynard T, Cadranel JF. Effect of terlipressin (Glypressin) on hepatorenal syndrome in cirrhotic patients: results of a multicentre pilot study. Eur J Gastroenterol Hepatol 2002;14:153-8. [PMID: 11981339 DOI: 10.1097/00042737-200202000-00009] [Cited by in Crossref: 91] [Cited by in F6Publishing: 84] [Article Influence: 4.3] [Reference Citation Analysis]
554 Dagher L, Moore K. The hepatorenal syndrome. Gut 2001;49:729-37. [PMID: 11600480 DOI: 10.1136/gut.49.5.729] [Cited by in Crossref: 68] [Cited by in F6Publishing: 66] [Article Influence: 3.1] [Reference Citation Analysis]
555 Wongcharatrawee S, Garcia-Tsao G. Clinical management of ascites and its complications. Clin Liver Dis 2001;5:833-50. [PMID: 11565143 DOI: 10.1016/s1089-3261(05)70194-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.4] [Reference Citation Analysis]
556 Kim WR. Models predicting the natural history of cirrhosis and need for liver transplantation: . Current Opinion in Organ Transplantation 2001;6:107-13. [DOI: 10.1097/00075200-200106000-00002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
557 Steinman TI, Becker BN, Frost AE, Olthoff KM, Smart FW, Suki WN, Wilkinson AH. GUIDELINES FOR THE REFERRAL AND MANAGEMENT OF PATIENTS ELIGIBLE FOR SOLID ORGAN TRANSPLANTATION: . Transplantation 2001;71:1189-204. [DOI: 10.1097/00007890-200105150-00001] [Cited by in Crossref: 152] [Cited by in F6Publishing: 153] [Article Influence: 6.9] [Reference Citation Analysis]
558 Schepke M, Sauerbruch T. Transjugular portosystemic stent shunt in treatment of liver diseases. World J Gastroenterol 2001; 7(2): 170-174 [PMID: 11819756 DOI: 10.3748/wjg.v7.i2.170] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
559 Garcia-Tsao G. Current management of the complications of cirrhosis and portal hypertension: variceal hemorrhage, ascites, and spontaneous bacterial peritonitis. Gastroenterology 2001;120:726-48. [PMID: 11179247 DOI: 10.1053/gast.2001.22580] [Cited by in Crossref: 303] [Cited by in F6Publishing: 330] [Article Influence: 13.8] [Reference Citation Analysis]
560 Geiger H, Leuschner U. Leberzirrhose und Nierenfunktionsstörungen. Therapie von Leber- und Gallekrankheiten 2001. [DOI: 10.1007/978-3-642-56819-0_32] [Reference Citation Analysis]
561 Carreiro G, Moreira ADL, Murad FF, Azevedo F, Coelho HSM. TIPS - anastomose portossistêmica intra-hepática transjugular. Revisão. Arq Gastroenterol 2001;38:69-80. [DOI: 10.1590/s0004-28032001000100013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.1] [Reference Citation Analysis]
562 Fernández-Esparrach G, Sánchez-Fueyo A, Ginès P, Uriz J, Quintó L, Ventura PJ, Cárdenas A, Guevara M, Sort P, Jiménez W, Bataller R, Arroyo V, Rodés J. A prognostic model for predicting survival in cirrhosis with ascites. J Hepatol 2001;34:46-52. [PMID: 11211907 DOI: 10.1016/s0168-8278(00)00011-8] [Cited by in Crossref: 175] [Cited by in F6Publishing: 175] [Article Influence: 8.0] [Reference Citation Analysis]
563 Anand BS. Drug Treatment of the Complications of Cirrhosis in the Older Adult: . Drugs & Aging 2001;18:575-85. [DOI: 10.2165/00002512-200118080-00002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.3] [Reference Citation Analysis]
564 Sanyal AJ. The use and misuse of transjugular intrahepatic portasystemic shunts. Curr Gastroenterol Rep. 2000;2:61-71. [PMID: 10981005 DOI: 10.1007/s11894-000-0053-5] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 1.0] [Reference Citation Analysis]
565 Planas R, Bataller R, Rodés J. Hepatorenal Syndrome. Curr Treat Options Gastroenterol 2000;3:445-50. [PMID: 11096604 DOI: 10.1007/s11938-000-0032-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.2] [Reference Citation Analysis]
566 Ginès P. Diagnosis and treatment of hepatorenal syndrome. Baillieres Best Pract Res Clin Gastroenterol 2000;14:945-57. [PMID: 11139348 DOI: 10.1053/bega.2000.0140] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.4] [Reference Citation Analysis]
567 Stoyanova II, Gulubova MV. Immunocytochemical study on the liver innervation in patients with cirrhosis. Acta Histochem 2000;102:391-402. [PMID: 11145532 DOI: 10.1078/0065-1281-00568] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 0.7] [Reference Citation Analysis]
568 Pham PT, Pham PC, Wilkinson AH. The kidney in liver transplantation. Clin Liver Dis 2000;4:567-90. [PMID: 11232162 DOI: 10.1016/s1089-3261(05)70127-6] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 1.0] [Reference Citation Analysis]
569 Saab S, Han SH, Martin P. Liver transplantation. Selection, listing criteria, and preoperative management. Clin Liver Dis 2000;4:513-32. [PMID: 11232159 DOI: 10.1016/s1089-3261(05)70124-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 0.3] [Reference Citation Analysis]
570 Brensing KA, Textor J, Perz J, Schiedermaier P, Raab P, Strunk H, Klehr HU, Kramer HJ, Spengler U, Schild H, Sauerbruch T. Long term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant cirrhotics with hepatorenal syndrome: a phase II study. Gut 2000;47:288-95. [PMID: 10896924 DOI: 10.1136/gut.47.2.288] [Cited by in Crossref: 331] [Cited by in F6Publishing: 294] [Article Influence: 14.4] [Reference Citation Analysis]
571 Eckardt K, Frei U. Reversibility of hepatorenal syndrome in an anuric patient with Child C cirrhosis requiring haemodialysis for 7 weeks. Nephrology Dialysis Transplantation 2000;15:1063-5. [DOI: 10.1093/ndt/15.7.1063] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
572 Mitzner SR, Stange J, Klammt S, Risler T, Erley CM, Bader BD, Berger ED, Lauchart W, Peszynski P, Freytag J, Hickstein H, Loock J, Löhr JM, Liebe S, Emmrich J, Korten G, Schmidt R. Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective, randomized, controlled clinical trial. Liver Transpl 2000;6:277-86. [PMID: 10827226 DOI: 10.1002/lt.500060326] [Cited by in Crossref: 16] [Cited by in F6Publishing: 98] [Article Influence: 0.7] [Reference Citation Analysis]
573 Bataller R, Ginès P, Arroyo V, Rodés J. Hepatorenal syndrome. Clin Liver Dis 2000;4:487-507. [PMID: 11232202 DOI: 10.1016/s1089-3261(05)70120-3] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 0.9] [Reference Citation Analysis]
574 Dagher L, Patch D, Marley R, Moore K, Burroughs A. Review article: pharmacological treatment of the hepatorenal syndrome in cirrhotic patients. Aliment Pharmacol Ther 2000;14:515-21. [PMID: 10792112 DOI: 10.1046/j.1365-2036.2000.00740.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 0.8] [Reference Citation Analysis]
575 Cantley L, Joannidis M. Kidney and Electrolyte Disturbances. Handbook of Alcoholism 2000. [DOI: 10.1201/9781420036961.ch19] [Reference Citation Analysis]
576 Wong F, Blendis L. Hepatorenal failure. Clin Liver Dis 2000;4:169-89. [PMID: 11232183 DOI: 10.1016/s1089-3261(05)70102-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.3] [Reference Citation Analysis]
577 Gatta A, Bolognesi M. Pathophysiology of Portal Hypertension. Portal Hypertension 2000. [DOI: 10.1007/978-3-642-57116-9_1] [Reference Citation Analysis]
578 Phillips MG, Harry R, Wendon J. The Hepatorenal Syndrome. Yearbook of Intensive Care and Emergency Medicine 2000. [DOI: 10.1007/978-3-662-13455-9_34] [Reference Citation Analysis]
579 Uriz J. Ascitis cirrótica. Fisiopatología, métodos diagnósticos y síndrome hepatorrenal. Medicine - Programa de Formación Médica Continuada Acreditado 2000;8:493-501. [DOI: 10.1016/s0304-5412(00)70096-5] [Reference Citation Analysis]
580 Cardellach F, Ginès Rolando Ortega P, Ortega R, Uriz J. Síndrome hepatorrenal: nuevos aspectos fisiopatológicos y terapéuticos. Medicina Clínica 2000;115:549-557. [DOI: 10.1016/s0025-7753(00)71620-4] [Reference Citation Analysis]
581 Gentilini P, Laffi G, La Villa G, Romanelli RG, Blendis LM. Ascites and hepatorenal syndrome during cirrhosis: two entities or the continuation of the same complication? J Hepatol 1999;31:1088-97. [PMID: 10604585 DOI: 10.1016/s0168-8278(99)80324-9] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 0.7] [Reference Citation Analysis]
582 Gülberg V, Bilzer M, Gerbes AL. Long-term therapy and retreatment of hepatorenal syndrome type 1 with ornipressin and dopamine. Hepatology 1999;30:870-5. [PMID: 10498636 DOI: 10.1002/hep.510300430] [Cited by in Crossref: 138] [Cited by in F6Publishing: 115] [Article Influence: 5.8] [Reference Citation Analysis]
583 Ginès P, Arroyo V. Hepatorenal Syndrome. JASN 1999;10:1833-9. [DOI: 10.1681/asn.v1081833] [Cited by in Crossref: 55] [Cited by in F6Publishing: 55] [Article Influence: 2.3] [Reference Citation Analysis]
584 Angeli P, Volpin R, Gerunda G, Craighero R, Roner P, Merenda R, Amodio P, Sticca A, Caregaro L, Maffei-Faccioli A, Gatta A. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology 1999;29:1690-7. [PMID: 10347109 DOI: 10.1002/hep.510290629] [Cited by in Crossref: 381] [Cited by in F6Publishing: 334] [Article Influence: 15.9] [Reference Citation Analysis]
585 Keeffe EB. Patient selection and listing policies for liver transplantation. J Gastroenterol Hepatol 1999;14 Suppl:S42-7. [PMID: 10382638 DOI: 10.1046/j.1440-1746.1999.01876.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
586 Deschênes M, Dufresne MP, Bui B, Fenyves D, Spahr L, Roy L, Lafortune M, Pomier-Layrargues G. Predictors of clinical response to transjugular intrahepatic portosystemic shunt (TIPS) in cirrhotic patients with refractory ascites. Am J Gastroenterol 1999;94:1361-5. [PMID: 10235219 DOI: 10.1111/j.1572-0241.1999.01112.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 1.0] [Reference Citation Analysis]
587 Rincón AR, Covarrubias A, Pedraza-chaverrí J, Poo JL, Armendáriz-borunda J, Panduro A. Differential effect of CCl4 on renal function in cirrhotic and non-cirrhotic rats. Experimental and Toxicologic Pathology 1999;51:199-205. [DOI: 10.1016/s0940-2993(99)80094-3] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 0.8] [Reference Citation Analysis]
588 Pape GR, Sauerbruch T. Leberkrankheiten. Therapie innerer Krankheiten 1999. [DOI: 10.1007/978-3-662-10477-4_42] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
589 Butt AK, Khan AA, Alam A, Shah SW, Shafqat F, Naqvi AB. Predicting hospital mortality in cirrhotic patients: comparison of Child-Pugh and Acute Physiology, Age and Chronic Health Evaluation (APACHE III) scoring systems. Am J Gastroenterol 1998;93:2469-75. [PMID: 9860411 DOI: 10.1111/j.1572-0241.1998.00706.x] [Cited by in Crossref: 38] [Cited by in F6Publishing: 32] [Article Influence: 1.5] [Reference Citation Analysis]
590 Lucey MR, Brown KA, Everson GT, Fung JJ, Gish R, Keefe EB, Kneteman NM, Lake JR, Martin P, Rakela J. Minimal criteria for placement of adults on the liver transplant waiting list: a report of a national conference organized by the American Society of Transplant Physicians and the American Association for the Study of Liver Diseases. Transplantation. 1998;66:956-962. [PMID: 9798717 DOI: 10.1097/00007890-199810150-00034] [Cited by in Crossref: 72] [Cited by in F6Publishing: 75] [Article Influence: 2.9] [Reference Citation Analysis]
591 Hadengue A, Gadano A, Moreau R, Giostra E, Durand F, Valla D, Erlinger S, Lebrec D. Beneficial effects of the 2-day administration of terlipressin in patients with cirrhosis and hepatorenal syndrome. J Hepatol 1998;29:565-70. [PMID: 9824265 DOI: 10.1016/s0168-8278(98)80151-7] [Cited by in Crossref: 150] [Cited by in F6Publishing: 162] [Article Influence: 6.0] [Reference Citation Analysis]
592 Schrier RW, Fassett RG, Ohara M, Martin P. Pathophysiology of renal fluid retention. Kidney International 1998;54:S127-32. [DOI: 10.1046/j.1523-1755.1998.06724.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 1.0] [Reference Citation Analysis]
593 Henriksen JH, Møller S, Ring-Larsen H, Christensen NJ. The sympathetic nervous system in liver disease. J Hepatol 1998;29:328-41. [PMID: 9722218 DOI: 10.1016/s0168-8278(98)80022-6] [Cited by in Crossref: 103] [Cited by in F6Publishing: 105] [Article Influence: 4.1] [Reference Citation Analysis]
594 Guevara M, Ginès P, Bandi JC, Gilabert R, Sort P, Jiménez W, Garcia-Pagan JC, Bosch J, Arroyo V, Rodés J. Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: effects on renal function and vasoactive systems. Hepatology 1998;28:416-22. [PMID: 9696006 DOI: 10.1002/hep.510280219] [Cited by in Crossref: 280] [Cited by in F6Publishing: 239] [Article Influence: 11.2] [Reference Citation Analysis]
595 González E, Rimola A, Navasa M, Andreu H, Grande L, García-Valdecasas JC, Cirera I, Visa J, Rodés J. Liver transplantation in patients with non-biliary cirrhosis: prognostic value of preoperative factors. J Hepatol 1998;28:320-8. [PMID: 9514545 DOI: 10.1016/0168-8278(88)80020-5] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 0.6] [Reference Citation Analysis]
596 McGuire BM, Bloomer JR. Complications of cirrhosis. Why they occur and what to do about them. Postgrad Med 1998;103:209-12, 217-8, 223-4. [PMID: 9479317 DOI: 10.3810/pgm.1998.02.361] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.3] [Reference Citation Analysis]
597 Arroyo V, Sort P, Ginés P. The kidney in liver disease. Critical Care Nephrology 1998. [DOI: 10.1007/978-94-011-5482-6_78] [Reference Citation Analysis]
598 Guevara M, Ginès P, Fernández-Esparrach G, Sort P, Salmerón JM, Jiménez W, Arroyo V, Rodés J. Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion. Hepatology 1998;27:35-41. [PMID: 9425914 DOI: 10.1002/hep.510270107] [Cited by in Crossref: 234] [Cited by in F6Publishing: 243] [Article Influence: 9.4] [Reference Citation Analysis]
599 Jalan R, Hayes PC. Hepatic encephalopathy and ascites. Lancet 1997;350:1309-15. [PMID: 9357420 DOI: 10.1016/S0140-6736(97)07503-X] [Cited by in Crossref: 57] [Cited by in F6Publishing: 60] [Article Influence: 2.2] [Reference Citation Analysis]
600 Jenkins SA, Shields R, Davies M, Elias E, Turnbull AJ, Bassendine MF, James OF, Iredale JP, Vyas SK, Arthur MJ, Kingsnorth AN, Sutton R. A multicentre randomised trial comparing octreotide and injection sclerotherapy in the management and outcome of acute variceal haemorrhage. Gut 1997;41:526-33. [PMID: 9391254 DOI: 10.1136/gut.41.4.526] [Cited by in Crossref: 77] [Cited by in F6Publishing: 77] [Article Influence: 3.0] [Reference Citation Analysis]
601 D'Amico G, Luca A. Natural history. Clinical-haemodynamic correlations. Prediction of the risk of bleeding. Baillieres Clin Gastroenterol 1997;11:243-56. [PMID: 9395746 DOI: 10.1016/s0950-3528(97)90038-5] [Cited by in Crossref: 160] [Cited by in F6Publishing: 164] [Article Influence: 6.2] [Reference Citation Analysis]
602 Wong F, Girgrah N, Blendis L. Review: the controversy over the pathophysiology of ascites formation in cirrhosis. J Gastroenterol Hepatol 1997;12:437-44. [PMID: 9195401 DOI: 10.1111/j.1440-1746.1997.tb00463.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.4] [Reference Citation Analysis]
603 Ginès P, Fernández-Esparrach G, Arroyo V. Ascites and renal functional abnormalities in cirrhosis. Pathogenesis and treatment. Baillieres Clin Gastroenterol 1997;11:365-85. [PMID: 9395753 DOI: 10.1016/s0950-3528(97)90045-2] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 0.5] [Reference Citation Analysis]
604 Ginès P, Arroyo V, Rodès J. Pathophysiology, complications, and treatment of ascites. Clin Liver Dis 1997;1:129-55. [PMID: 15562674 DOI: 10.1016/s1089-3261(05)70261-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 0.5] [Reference Citation Analysis]
605 Brensing KA, Textor J, Strunk H, Klehr HU, Schild H, Sauerbruch T. Transjugular intrahepatic portosystemic stent-shunt for hepatorenal syndrome. Lancet 1997;349:697-8. [PMID: 9078203 DOI: 10.1016/s0140-6736(97)24010-9] [Cited by in Crossref: 68] [Cited by in F6Publishing: 70] [Article Influence: 2.6] [Reference Citation Analysis]
606 Saló J, Ginès A, Quer JC, Fernández-Esparrach G, Guevara M, Ginès P, Bataller R, Planas R, Jiménez W, Arroyo V, Rodés J. Renal and neurohormonal changes following simultaneous administration of systemic vasoconstrictors and dopamine or prostacyclin in cirrhotic patients with hepatorenal syndrome. J Hepatol 1996;25:916-23. [PMID: 9007721 DOI: 10.1016/s0168-8278(96)80297-2] [Cited by in Crossref: 37] [Cited by in F6Publishing: 40] [Article Influence: 1.4] [Reference Citation Analysis]
607 Roberts LR, Kamath PS. Ascites and hepatorenal syndrome: pathophysiology and management. Mayo Clin Proc 1996;71:874-81. [PMID: 8790265 DOI: 10.4065/71.9.874] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 1.0] [Reference Citation Analysis]
608 Kelley SD. Scenario number one: Discussant-Kelley. Liver Transpl 1996;2:72-77. [DOI: 10.1002/lt.500020114] [Reference Citation Analysis]
609 Arroyo V, Ginès P, Gerbes AL, Dudley FJ, Gentilini P, Laffi G, Reynolds TB, Ring-Larsen H, Schölmerich J. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology 1996;23:164-76. [PMID: 8550036 DOI: 10.1002/hep.510230122] [Cited by in Crossref: 1081] [Cited by in F6Publishing: 1116] [Article Influence: 40.0] [Reference Citation Analysis]
610 Simpson KJ, Finlayson ND. Clinical evaluation of liver disease. Baillieres Clin Gastroenterol 1995;9:639-59. [PMID: 8903798 DOI: 10.1016/0950-3528(95)90054-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 0.3] [Reference Citation Analysis]
611 Hsia HC, Lin HC, Tsai YT, Lee FY, Hwang CC, Hou MC, Lee SD. The effects of chronic administration of indomethacin and misoprostol on renal function in cirrhotic patients with and without ascites. Scand J Gastroenterol 1995;30:1194-9. [PMID: 9053973 DOI: 10.3109/00365529509101630] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 0.5] [Reference Citation Analysis]
612 Tsai YT, Lin HC, Yang MC, Lee FY, Hou MC, Chen LS, Lee SD. Plasma endothelin levels in patients with cirrhosis and their relationships to the severity of cirrhosis and renal function. J Hepatol 1995;23:681-8. [PMID: 8750167 DOI: 10.1016/0168-8278(95)80034-4] [Cited by in Crossref: 43] [Cited by in F6Publishing: 39] [Article Influence: 1.5] [Reference Citation Analysis]
613 Martin P, Schrier RW. Renal Sodium Excretion and Edematous Disorders. Endocrinology and Metabolism Clinics of North America 1995;24:459-79. [DOI: 10.1016/s0889-8529(18)30027-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
614 Mendenhall C, Roselle GA, Gartside P, Moritz T. Relationship of protein calorie malnutrition to alcoholic liver disease: a reexamination of data from two Veterans Administration Cooperative Studies. Alcohol Clin Exp Res 1995;19:635-41. [PMID: 7573786 DOI: 10.1111/j.1530-0277.1995.tb01560.x] [Cited by in Crossref: 158] [Cited by in F6Publishing: 155] [Article Influence: 5.6] [Reference Citation Analysis]
615 Keller F, Heinze H, Jochimsen F, Passfall J, Schuppan D, Büttner P. Risk factors and outcome of 107 patients with decompensated liver disease and acute renal failure (including 26 patients with hepatorenal syndrome): the role of hemodialysis. Ren Fail 1995;17:135-46. [PMID: 7644764 DOI: 10.3109/08860229509026250] [Cited by in Crossref: 64] [Cited by in F6Publishing: 66] [Article Influence: 2.3] [Reference Citation Analysis]
616 Abuelo JG. Vascular causes of renal failure. Renal Failure 1995. [DOI: 10.1007/978-94-011-0047-2_10] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.0] [Reference Citation Analysis]
617 Follo A, Llovet JM, Navasa M, Planas R, Forns X, Francitorra A, Rimola A, Gassull MA, Arroyo V, Rodés J. Renal impairment after spontaneous bacterial peritonitis in cirrhosis: incidence, clinical course, predictive factors and prognosis. Hepatology 1994;20:1495-501. [PMID: 7982650 DOI: 10.1002/hep.1840200619] [Cited by in Crossref: 382] [Cited by in F6Publishing: 382] [Article Influence: 13.2] [Reference Citation Analysis]
618 Castells A, Saló J, Planas R, Quer JC, Ginès A, Boix J, Ginès P, Gassull MA, Terés J, Arroyo V. Impact of shunt surgery for variceal bleeding in the natural history of ascites in cirrhosis: a retrospective study. Hepatology 1994;20:584-91. [PMID: 8076916] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 1.1] [Reference Citation Analysis]
619 Craig RM. Precision in nutritional diagnoses. Gastroenterology 1993;105:1923. [PMID: 8253374 DOI: 10.1016/0016-5085(93)91103-o] [Reference Citation Analysis]